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Abstract 
Randomized clinical trials (RCTs) provide important evidence to inform clinical decision 
making; if these trials are of low quality, the resulting clinical decision will likely also be 
of low quality. The main purpose of this thesis was to conduct a series of methodological 
surveys that would identify potential areas of improvement in the quality of reporting for 
RCTs published in anesthesiology journals. Trial registration adequacy, adherence to 
CONSORT for Abstracts guidelines, and sample size calculation quality were all 
assessed, with a final chapter exploring the effect of industry funding on these 
methodological quality measures. While the results suggest improvement over time, the 
overall quality is still lacking. Industry sources funded a minority of the included RCTs, 
and did not appear to affect any of the measures of quality. More research is needed to 
confirm these findings and to identify tools for reducing the potential distortion 
emanating from low quality design and reporting.  
Keywords 
Randomized clinical trial, Trial registration, CONSORT for abstracts, Sample size, 
Statistical power, Industry funding, Study design, Reporting quality. 
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Chapter 1  
1 Introduction 
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1.1 Background 
First coined by Gordon Guyatt in 1991,1 evidence-based medicine (EBM) involves 
identifying the best available evidence, deciding the accuracy and reliability of that 
evidence, considering the trade-offs to alternative management strategies, and integrating 
patients’ values and preferences so that the optimal clinical decision can be made.2 The 
first of these principles is also one of the most important since, without relevant evidence, 
the process of EBM cannot be started. That is not to say that individual clinical expertise 
is unimportant, as the proponents of EBM have always emphasized the concept of 
integrating the best available evidence with clinical expertise.3 In regards to therapy 
decisions, large randomized trials are at the top of the evidence hierarchy,2 representing 
the best type of evidence when available. Randomized trials (and systematic reviews of 
multiple randomized trials) are the gold standard for determining whether a treatment is 
more beneficial than harmful.3  
A randomized clinical trial (RCT) is a prospective cohort study where participants are 
allocated by chance to treatment and control groups.4 Ideally, randomization eliminates 
selection bias since participants are randomly assigned to each study arm. Randomization 
also reduces confounding since both known and unknown potentially confounding patient 
factors are randomly distributed between study arms.4 Even though RCTs are the best 
type of evidence, confidence in their results is decreased when there are design, 
execution, or reporting problems leading to a high risk of bias.2 If low quality RCTs are 
used to make clinical decisions, those clinical decisions are likely to also be of low 
quality.  
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This thesis will focus on four aspects relating to the quality of reporting in RCTs: trial 
registration, abstract reporting guidelines, sample size calculations, and funding source. 
While some investigators have analyzed these factors in the top general medical journals, 
this thesis will focus specifically on the anesthesiology literature to provide a specialty-
specific point of view; specifically, only RCTs published from the top six general (non-
pain-centric) anesthesiology journals are included in the following chapters: Anaesthesia, 
Anesthesia & Analgesia (A&A), Anesthesiology, British Journal of Anaesthesia (BJA), 
Canadian Journal of Anesthesia (CJA), and European Journal of Anaesthesiology 
(EJA).5  
1.2 Thesis Rationale 
To ensure that the RCTs used for clinical decision making are useful, authors must ensure 
that their studies are appropriately designed, executed, and reported.2 The key message in 
EBM is best available evidence: however, if the RCTs being used to make clinical 
decisions are distorted or biased, how can they provide reliable evidence? Distortion 
occurs when the design quality or reporting quality of a trial causes its true findings to 
become obscured, either through intentional or unintentional misrepresentation. This 
thesis reviews published RCTs in anesthesiology journals to evaluate and improve design 
quality by assessing trial registration, adequacy of sample size calculations, and the role 
(if any) of the trials’ funding source. This thesis also examines reporting quality by 
assessing adherence to abstract reporting guidelines and discrepancies between reported 
and registered outcomes. 
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Adequate trial registration involves prospectively recording, in a publicly available trial 
registry, the precise intervention to be tested and outcomes to be measured, prior to the 
first patient being enrolled. The process of adequate trial registration aims to reduce 
publication and outcome reporting bias, thereby improving transparency.6 Publication 
bias involves publication of research findings based on the nature and direction of the 
results while outcome reporting bias involves selectively reporting outcomes based on the 
nature and direction of the results.7 If trials are registered before they are conducted, there 
would be a record regardless of whether or not they are published.6 The issue of selective 
outcome reporting is also easier to recognize since readers and editors are able to 
compare what the investigators had stated in the registry with what they report in their 
manuscript. The 2005 statement from the International Committee of Medical Journal 
Editors (ICMJE) states that all ICMJE member journals will require registration in a 
public trials registry for a RCT to be considered for publication,8 demonstrating the 
importance of adequate trial registration.  
Recently, the Centre for Evidence-Based Medicine Outcome Monitoring Project 
(COMPare) team checked RCTs published in the top five medical journals for outcome 
switching and sent letters to the journal editors with their findings.9 Of the 67 trials 
checked, they found that on average, each trial only reported 58.2% of their specified 
outcomes and added 5.3 new outcomes that were never registered.9 Of the 201 RCTs 
published in top anesthesiology journals in 2013, only 36% in 2013 were adequately 
registered and 48% of those adequately registered RCTs had a major discrepancy 
between the trial registry and the published manuscript, suggesting an unacceptably high 
prevalence of outcome reporting bias.10 Chapter 3 of this thesis will further explore this 
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issue by examining the trial registration rates and outcome discrepancy rates over time 
and between anesthesiology journals. By quantifying how often investigators are 
switching outcomes, authors may appreciate why they need to avoid this practice and 
journal editors will be able to identify these problems — potentially reducing publication 
bias and selective outcome reporting bias. 
Another important aspect of trial reporting is the abstract of the published paper. Since 
abstracts are concise summaries of the entire RCT, clinicians and other readers often use 
the abstract to decide whether or not to read the full manuscript.11 Due mainly to time 
constraints, many readers will never read any part of the paper except the abstract.12 In 
other cases, the full-text may be irretrievable due to limited resources or language 
barriers.13 Either way, it is clear that abstracts are extremely important in biomedical 
publishing, and it is likely that at least some of current clinical practice is being based 
solely on the evidence presented in abstracts.13 In 2008, the Consolidated Standards of 
Reporting Trials for Abstracts (CONSORT for Abstracts) statement provided a list of 
essential items authors should include in abstracts when reporting trial results.14,15 
Comparing 2006 (pre-CONSORT for Abstracts) and 2009 (post-CONSORT for 
Abstracts) abstracts published in four anesthesiology journals, there were no clear 
improvements observed, with well-reported items continuing to be well-reported and 
poorly reported items remaining poorly reported.16 Chapter 4 of this thesis updates the 
anesthesiology literature regarding the quality of RCT abstract reporting and determines 
whether abstracts are distorting the trials’ findings by leaving items from the full-text 
manuscript out of the abstract. 
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Every RCT needs participants. However, determining the ideal number of participants 
that balances limited resources and the ability to detect an effect is difficult. The main 
objective of sample size estimation is to determine the minimum number of participants 
needed to detect a clinically relevant effect for the intervention.17 The CONSORT 
statement recognizes the importance of sample size calculations, and recommends that 
authors should include how sample size was determined when publishing their findings.18 
Researchers found that even though sample size calculations were frequently reported 
(91.7%) in anesthesiology RCTs published in 2013, the required assumptions to replicate 
the sample size calculations were not consistently reported, with differences found 
between the estimated effect used for the sample size calculation and the actual values 
observed in the RCT.19 Since these effect differences for each RCT were not quantified, 
chapter 5 of this thesis will help to show how many trials actually had different values 
than what was anticipated in the sample size calculations. This chapter will also look at 
the progress of anesthesiology RCTs from 2010 to 2016 in terms of sample size 
calculation quality, updating the literature using the most recently published trials.  
In chapter 6, the role that the funding source has on RCTs will be explored using the 
outcomes measured in previous chapters. With the increased support from industry for 
biomedical research over the years, potential conflicts of interest stemming from financial 
interests have often been problematic for maintaining scientific integrity.20 When the 
pharmaceutical industry and other related biotechnology firms fund clinical trials, 
achieving favourable results in those trials are critical to the company and there are 
financial pressures to achieve a certain outcome.21 While many studies have shown that 
industry funded studies are more likely to have outcomes favouring the sponsor,22 none 
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have focused on the effect in anesthesiology literature. This chapter fills that gap as well 
as examines the effect of industry funding using less commonly studied quality indicators 
such as trial registration adequacy, abstract reporting guidelines adherence, and sample 
size calculation quality to provide a different perspective on the discussion.  
1.3 Thesis Objectives 
As suggested by the title, the overall aim of this thesis is to identify areas where authors 
can reduce distortion and improve the quality of RCTs published in anesthesiology 
journals. To accomplish this objective, each of chapters 3 to 6 addresses one potential 
concept that authors may not have fully considered when designing, executing, and 
reporting their RCTs.  
The first objective (Chapter 3) is to determine whether the reported outcomes of RCTs 
published in anesthesiology journals are the same as the outcomes originally registered 
by the investigators in publicly available clinical trial registries. Potential trends for this 
objective will be observed both across time and between journals.  
The second objective (Chapter 4) involves determining the degree of adherence to 
CONSORT reporting guidelines for the abstracts of RCTs published in anesthesiology 
journals. The full-text manuscript will also be searched for items left out of the abstract to 
determine whether these abstracts are distorting the overall meaning of the trial (i.e. 
required items are reported in the full manuscript but not in the abstract). 
The third objective (Chapter 5) is to determine whether the quality of conducting sample 
size calculations has improved from 2010 to 2016 for RCTs published in anesthesiology 
journals. The quality will be ascertained in two ways, by assessing whether authors report 
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the necessary elements to allow for replication of sample size calculations and whether 
the assumptions made by authors are similar to the values actually observed after 
conducting the trial. Using values reported in the manuscript, the post-hoc power for 
primary and secondary outcomes will also be calculated to determine whether there was 
enough statistical power to detect differences between study groups. 
The fourth and final objective (Chapter 6) seeks to understand whether the funding 
source, namely industry funding, introduces biases to RCTs published in anesthesiology 
journals. This objective will show what types of funding sources support anesthesiology 
RCTs and whether industry funding affects the objectives outlined in earlier chapters 
such as registration rates, registered compared to reported outcomes, adherence to the 
CONSORT for Abstracts statement, quality of sample size calculations, etc.  
1.4 Thesis Structure 
In compliance with the standards set by The University of Western Ontario’s School of 
Graduate and Postdoctoral Studies, this thesis is presented in the integrated-article 
format.23 Chapter 2 provides a detailed and critical review of the literature pertaining to 
the quality of reporting for RCTs published in anesthesiology journals. This chapter 
comprehensively surveys and appraises the literature in regards to subject material 
presented in subsequent chapters such as anesthesiology, RCTs, the CONSORT 
statement, trial registration, sample size, and funding source impact. Each chapter from 3 
to 6 is a manuscript that achieves one of the objectives described in the previous section.  
Chapter 3, Comparison of registered and reported outcomes in randomized clinical trials 
published in anesthesiology journals, addresses the first objective, chapter 4, The degree 
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of adherence to CONSORT reporting guidelines for the abstracts of randomized clinical 
trials published in anesthesiology journals, addresses the second objective, chapter 5, 
Sample size calculations for randomized clinical trials published in anesthesiology 
journals: A comparison of 2010 versus 2016, addresses the third objective, and chapter 6, 
Impact of funding source on randomized clinical trials published in anesthesiology 
journals, addresses the fourth objective. Each individual chapter from 3 to 6 addresses 
discrete but related topics, with the intention of submitting each chapter as a separate 
manuscript for publication. 
Chapter 3 is an extension of my undergraduate thesis24 completed in partial fulfillment of 
the requirements for the degree of Bachelor of Medical Sciences, Honors Specialization 
in Epidemiology and Biostatistics. This undergraduate thesis (work performed before 
beginning the MSc degree) comprised the searching, screening, and extracting of data 
relating to study characteristics and registration status of eligible studies24 while the rest 
of Chapter 3 is new work that determines the degree of primary and secondary outcome 
discrepancies in the included studies. Chapter 7, Integrated Discussion and General 
Conclusions, summarizes the main results of this thesis and relates each chapter’s 
findings to each other.  
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Chapter 2  
2 Literature Review 
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2.1 Anesthesiology 
One of the many specialties in medicine, anesthesiology is concerned with pain 
management, administering anesthesia, airway management, advanced life support, and 
perioperative care.1 Because of the diverse nature of anesthesiology, anesthesiologists 
practice in a wide variety of settings such as in the operating room, where they are 
responsible for medical management and anesthetic care of patients; in the postanesthesia 
care unit, where they monitor and assess patients regaining consciousness; in pain 
management clinics, where they relieve pain for patients; and in critical care units, where 
they provide medical assessment, airway management, and respiratory support.2 The field 
of anesthesiology is also referred to as anaesthesiology, anaesthesia, and anesthesia, with 
practitioners termed an(a)esthesiologists or an(a)esthetists.  
In Canada, only physicians can have the responsibility for administering anesthesia, but 
may delegate certain tasks to anesthesia assistants or technicians.3 The same situation 
occurs in the United States, with the exception of certified registered nurse anesthetists 
also able to administer anesthesia with or without physician supervision.3,4 In Canada, the 
number of physicians in the anesthesiology specialty has been rising with 3,274 
anesthesiologists in 2016, corresponding to 9.1 anesthesiologists per 100,000 people in 
the population.5 Excluding on-call, Canadian anesthesiologists spent, on average, only 
0.8 hours per week (1.6% of total hours worked per week excluding on-call) on research 
in 2014, with most of their time being spent on direct patient care and teaching.5 It is 
therefore apparent that most anesthesiologists are not researchers per se. 
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2.2 Randomized Clinical Trials 
A randomized clinical trial (RCT) is a prospective study that examines the effects of an 
intervention in human beings by randomly assigning participants to intervention and 
control groups, and following up on their health status at a later time.6 The term 
randomized clinical trial is often used interchangeably with the term, randomized 
controlled trial, and both terms share the same acronym of RCT. In evidence-based 
medicine (EBM), RCTs (and systematic reviews or meta-analyses of RCTs) are 
considered to be at the top of the evidence hierarchy for therapeutic interventions since 
they present the lowest risk of bias.7 The randomization aspect of RCTs reduces selection 
bias by having participants randomly allocated to study arms and reduces confounding by 
equally distributing subject characteristics between study arms.8  
The criticisms of EBM can be categorized into five broad themes: overreliance on 
empiricism independent of physiological theory, narrow definition of high quality 
evidence disregarding other types of research, lack of evidence regarding the efficacy of 
EBM to improve the quality of healthcare, limited applicability when treating an 
individual patient, and potential reduction in a physician’s autonomy to cut costs.9 The 
evidence hierarchy in EBM should not imply that RCTs are the best type of study, since 
maximizing internal validity typically comes at the cost of reducing external validity, 
generalizability, and applicability.10 
Looking at the number of publications from Canadian university anesthesiology 
departments in 2000 to 2004, RCTs were the most common type of study published at 
18%, followed by case reports, reviews, and cohort studies.11 However, the total number 
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of RCTs appeared to be decreasing from 2000 to 2004 even though the total number of 
anesthesia publications was constant with minor yearly fluctuations.11 A follow-up study 
in the years 2005 to 2013 found that the declining trend did not continue beyond 2004, 
resulting in a slight overall increase in RCTs published.12 A similar trend was observed in 
the United States with the overall number and percentage of clinical research studies 
increasing from 2001 to 2010.13 In the top seven general anesthesiology journals from 
1997 to 2006, the worldwide number of original research publications remained constant 
while the number of United Kingdom original research publications decreased by about 
50%.14 Unfortunately, the data was not stratified by type of publication, classifying 
original research publications as including all experimental research, RCTs, observational 
studies, and large case series with statistics applied.14  
2.3 Trial Registration  
2.3.1 Reasons for Trial Registration 
The purpose of trial registration is to ensure that there is a public record of all trials 
conducted and that investigators commit to a certain trial protocol before conducting the 
study. Adequate trial registration involves prospectively (before the first patient is 
enrolled) registering an RCT in a publicly available trials registry,15 ideally reducing 
publication bias and outcome reporting bias. While both biases fall under the general 
category of reporting bias, publication bias occurs at the study level while outcome 
reporting bias occurs at the outcome level.16   
Publication bias involves deciding whether to publish research findings based on the 
nature and direction of the results.17 This type of reporting bias has been extensively 
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studied, with a systematic review finding that positive trials were more likely to be 
published than negative or null trials (odds ratio (OR): 3.90; 95% confidence interval 
(CI): 2.68–5.65).18 Potential reasons for this finding include authors failing to write 
manuscripts for trials with negative results, trials with negative results being peer 
reviewed less favourably, or journal editors being reluctant to publish negative results.17 
However, among submitted manuscripts to Journal of the American Medical Association 
(JAMA), no statistically significant difference was found between the acceptance rates of 
submissions with positive results and negative results,19 suggesting that publication bias 
may be due more to lack of manuscript submission than lack of manuscript acceptance.20 
Further studies have confirmed the investigator-based factors for nonpublication, such as 
lack of time to prepare manuscript, perceived low likelihood of being published, and 
difficulties with co-investigators.21–23  
Trial registration aims to reduce publication bias by identifying all trials conducted, 
thereby encouraging investigators to publish their results after the trial has been 
completed.24 By ensuring all RCTs are registered prior to patient enrollment, a public 
record of all RCTs being conducted will remain even if trials fail to be published. Though 
trial registration has certainly not eliminated publication bias, more trials are being 
registered and public trials registries allow for the extent of publication bias to be fairly 
easily examined and monitored.25 In fact, a recent cross-sectional study of published 
randomized trials found the first inverse association between trial registration and 
significant positive outcomes in cardiovascular trials, suggesting that trial registration 
may already be starting to reduce publication bias.26  
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On the other hand, outcome reporting bias involves selectively reporting outcomes based 
on the nature and direction of individual outcomes’ results.17 Selective reporting can be 
divided into several subcategories: selective omission of outcomes, selective choice of 
data for an outcome such as reporting only one time point after many have been 
measured, selective reporting of analyses using the same data such as selecting from 
analyses using multiple cut-points, selective reporting of subsets of the data such as using 
only subscales of a full measurement scale that was measured, and selective under-
reporting of the data that prevents future meta-analyses.27 Selective outcome reporting 
affects the effect size and significance level estimates, resulting in less robust 
conclusions.28 Many studies have examined outcome reporting bias, with a systematic 
review finding that statistically significant outcomes were more likely to be completely 
reported than non-statistically significant outcomes with ORs ranging from 2.2 to 4.7.29 A 
survey of trial authors found that reasons for not reporting outcomes included lack of 
understanding about the importance of reporting negative results, the data perceived to be 
uninteresting, having too few events to be worth reporting, and perceived need for brevity 
from the journal.30 Since most unreported outcomes were due to a lack of a significant 
difference between study arms, published results would likely be overoptimistic and 
biased.30  
Trial registration requires investigators to publicly commit to outcomes prior to the study 
being conducted, reducing the chance of outcome reporting bias remaining undetected. 
Trial registration also makes the conduct and reporting of RCTs a more transparent 
process, with other researchers, reviewers, or editors able to compare the registered trial 
protocol with the final publication. One example of this occurring is the Centre for 
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Evidence-Based Medicine Outcome Monitoring Project (COMPare), where researchers 
monitor the RCTs published in the top five medical journals (Annals of Internal Medicine 
(Annals IM), the BMJ, JAMA, the New England Journal of Medicine (NEJM), and the 
Lancet) for outcome switching by comparing the trial protocol or trials registry entry with 
the trial report, writing letters to those journals and correcting the record for those trials.31 
Even though trial registration improves study conduct transparency, many of its benefits 
can only be seen if a large majority of RCTs are adequately registered, suggesting the 
need for mandatory trial registration.32 If unregistered or retrospectively registered trials 
can be published, some investigators may decide to only register a trial after a decision to 
publish is made, resulting in publication bias as there would be no record of unpublished 
studies.  
2.3.2 Mandatory Trial Registration 
In 2005, the International Committee of Medical Journal Editors (ICMJE) mandated that 
all member journals would require clinical trials to be registered in a public trials registry 
prior to patient enrollment in order to be considered for publication.33 While the ICMJE 
does not advocate for a specific trials registry, they require that the registry must be 
publicly available at no charge, open to all prospective registrants, managed by a not-for-
profit organization, possessing a mechanism to ensure registration data validity, and 
electronically searchable;33 the following registries are currently deemed acceptable: 
www.anzctr.org.au, www.clinicaltrials.gov, www.ISRCTN.org, 
www.umin.ac.jp/ctr/index/htm, www.trialregister.nl, https://eudract.ema.europa.eu/ (new 
registrations after 2011), and any registries that participate in the World Health 
Organization (WHO) International Clinical Trials Portal after June 2007 
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(http://www.who.int/ictrp/network/primary/en/index.html).34 Another association of 
medical journal editors, the World Association of Medical Editors (WAME) also has a 
policy that clinical trials should be registered at their inception.35  
The World Medical Association’s (WMA) Declaration of Helsinki is a statement of 
ethical principles for medical research where human participants are used.36 As part of 
this statement, the authors recommended that all research studies using human 
participants should be publicly registered prior to subject recruitment, suggesting that 
there is also an ethical obligation to prospectively register RCTs.36 In fact, the WHO also 
believes that trial registration is a “scientific, ethical and moral responsibility,” and has 
created an International Clinical Trials Registry Platform (ICTRP) to display entries from 
trial registries around the world.37 The Consolidated Standards of Reporting Trials 
(CONSORT) statement specifies trial registration as one of the mandatory reporting 
items, with authors required to either provide the name of the trial registry along with the 
registration number or a reason for not registering their trial.38 
In the United States, the first federal law to require trial registration for clinical trials 
conducted under investigational new drug applications was passed in 1997.39 In 2007, the 
Food and Drug Administration Amendments Act (FDAAA) was passed, with section 801 
expanding the requirements to include all clinical trials conducted in the United States or 
using interventions manufactured in the United States.40 However, there is currently no 
legislation in Canada regarding mandatory clinical trial registration, with Health Canada 
only encouraging sponsors to register their trials in publicly accessible registries41 even 
though the Tri-Council Policy Statement: Ethical Conduct for Research Involving 
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Humans (TCPS2) states that all clinical trials should be prospectively registered in a 
publicly accessible registry that is acceptable to the WHO or the ICMJE.42  
The instructions to authors or similarly named sections in journals describe guidelines for 
authors to follow when submitting to specific journals and serve as the main source of 
information regarding journal policies. A study using the ICMJE member journal list and 
CONSORT adopting journal list in 2011 found that only 47% of journals on the ICMJE 
list and 69% on the CONSORT list had a statement in the instructions to authors section 
about trial registration, with 90% and 94% of these statements explicitly requiring trial 
registration, respectively.43 These results are concerning as journals that are ICMJE 
members or CONSORT statement endorsers require trial registration, potentially 
misleading submitting authors on the journal’s policy by not being explicit about trial 
registration. In terms of anesthesiology journals, Anesthesiology, British Journal of 
Anaesthesia (BJA), and European Journal of Anaesthesiology (EJA) described their 
mandatory trial registration policy in their instructions to authors sections starting in 
2013,44 2009,45 and 2015,46 respectively. Anaesthesia and Anesthesia & Analgesia (A&A) 
both confirmed a mandatory trial registration policy after emails to the editorial 
office,47,48 while the Canadian Journal of Anesthesia (CJA) only strongly recommends 
trial registration in its instructions to authors.49  
2.3.3 Quality of Trial Registration 
Studies assessing study publication bias or outcome reporting bias found that the 
percentage of trial protocols resulting in a published manuscript ranged from 21–93%, 
but consistently showed that positive studies were more likely to be published compared 
to negative studies.50 However, another study found that trial registration was only 
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marginally associated with a RCT having positive findings.51 In terms of outcome 
reporting bias, 40–62% of trials had major discrepancies in the primary outcomes when 
comparing the protocol to the publication, with 13-31% of primary outcomes from the 
protocol not reported in the publication, 10–18% of primary outcomes reported in the 
publication but not described in the protocol, and statistically significant outcomes having 
higher odds of being fully reported.50  
Focusing on studies examining trial registration, the median proportion of studies with an 
identified primary outcome discrepancy between the trials registry entry and the 
publication was 31% (interquartile range (IQR): 17 to 45%).52 When able to be assessed, 
these outcome discrepancies often favoured statistically significant results with a median 
of 50% (IQR: 28 to 64%).52 The proportion of primary outcome discrepancies was highly 
variable among included studies,52 potentially because studies used different groups of 
RCTs from different specialties, journals, and time periods. This suggests that a 
specialty-specific perspective would provide the most accurate information about trial 
registration quality in a particular specialty.  
For RCTs published in the top five high impact factor anesthesiology journals in 2013 
(Anaesthesia, A&A, Anesthesiology, BJA, and Regional Anesthesia and Pain Medicine 
(RAPM)), only 35% were prospectively registered in a publicly accessible trials 
registry.53 When focusing on all RCTs registered, regardless of before or after patient 
enrollment, 48% had a major discrepancy between the trials registry and the 
publication.53 In Acta Anaesthesiologica Scandinavica (Acta), the registration rates were 
found to significantly increase from 17.1% in trials starting subject enrollment before 
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2010 to 63.2% in trials starting subject enrollment after 2010, when Acta had 
implemented mandatory registration for RCTs.54 
2.4 Abstract Reporting and the CONSORT Statement 
2.4.1 Abstracts 
An abstract is a concise summary of the entire published study and is often used by 
readers to determine whether or not to read the full-text.55 In fact, the full-text manuscript 
does not exist beyond its abstract for most readers since the abstract is the only part that 
potential referees read when invited to review a manuscript, the only part available when 
searching through electronic databases, and the only part quickly accessible after readers 
see an interesting title in a journal.56 For readers that decide to read the full-text, the 
abstract will have already left a first impression and set the tone for the rest of the text.56 
When reading medical journals, clinicians reported reading only the abstract about two 
thirds of the time, either using the abstract as a means for extracting information from the 
full-text or as a screening tool to determine which studies are actually worth reading.57 
Abstracts for RCTs can help clinicians quickly decide whether reading the full-text is 
worthwhile to ensure medical decisions are made with appropriate evidence. 
In addition, there may be financial, information technology, time, or language barriers 
that prevent or reduce access to all full-text manuscripts, increasing the importance of 
abstracts including all essential elements of the trial. Clinicians practising in community-
based settings or low income countries may not have the financial ability or appropriate 
technology to access all full-text manuscripts, potentially relying on publicly available 
abstracts as the only source for key RCT evidence.55 Busy clinicians also may not have 
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enough time to access or read many full-text manuscripts, leaving abstracts as the 
primary source of staying updated with new medical developments.58 Finally, language 
barriers may result in only abstracts being used to make clinical decisions since only 
translated versions of the abstract are easily available and accessible.59 Thus, abstracts are 
important tools for clinicians to make decisions about medical interventions; it is critical 
that they are reported comprehensively and accurately. 
2.4.2 CONSORT Statement 
There are numerous guidelines for RCTs, addressing both the trial protocol60 and the 
resulting publication. The most commonly used set of RCT reporting guidelines is the 
Consolidated Standards of Reporting Trials (CONSORT) statement, endorsed by over 
600 biomedical journals, the ICMJE, and the WAME.61 Recently updated in 2010, the 
CONSORT statement was published as a 25-item checklist with a flow diagram62–70 and 
as an explanation/elaboration document38,71 to improve the reporting of RCTs. Though 
RCTs are the gold standard for evaluating healthcare interventions, the results may be 
biased if RCTs are not properly designed or conducted.72 In order for readers to 
accurately assess the results of a RCT, complete and clear information needs to be 
adequately reported.62–70 Though the 2010 CONSORT statement is applicable for all 
RCTs, its main focus is for individually randomized, two group, parallel trials so 
extensions to the CONSORT statement have been developed to provide further 
guidance.62–70 One of the extensions to the CONSORT statement is the CONSORT for 
Abstracts statement, aimed at improving the reporting of RCT abstracts.73,74 The 
CONSORT for Abstracts statement was also integrated into the 2010 CONSORT 
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statement with a reference to refer to the CONSORT for Abstracts statement for specific 
guidance on reporting a structured abstract.62–70 
2.4.3 CONSORT for Abstracts 
The CONSORT for Abstracts statement was published in 2008 as a 17-item checklist,73 
with an accompanying explanation and elaboration document.74 The CONSORT for 
Abstracts statement specifies 16 essential items that need to be reported in journal 
abstracts for RCTs and an additional item for conference abstracts (Appendix A).73 To 
develop the checklist, authors created a list of items using existing tools for quality 
assessment and empirical evidence, then used a modified Delphi consensus method to 
select possible items for further discussion and revisions at the CONSORT group 
meeting.73 An important issue for improving abstract reporting is space limitation, but 
preliminary work showed that all checklist items could be included within a 250-300 
word limit.73 Contrary to popular belief, the current Medline character limit for abstracts 
is actually 10,000,75 allowing for much longer abstracts to be published if desired by 
journals. 
In 2006, most abstracts of RCTs published in four high impact, general medical journals 
specified the study type, study population, objectives, and trial interventions, but were 
deficient in reporting markers of methodological quality such as allocation concealment, 
blinding, use of intent-to-treat analysis, and extent of lost to follow-up.76 After the 
publication of the CONSORT for Abstracts statement, a study found that in five high 
impact, general medical journals, two journals (Annals IM and the Lancet) had an active 
policy to enforce the CONSORT for Abstracts guidelines and had an immediate increase 
in the mean number of items reported, while three journals (JAMA, NEJM, and the BMJ) 
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did not have an active policy to enforce the CONSORT for Abstracts guidelines and did 
not have any change in the mean number of items reported.77 However, for RCTs 
published in 2010 for four of those journals (the BMJ, JAMA, the Lancet, and NEJM), an 
analysis using an equal proportion of abstracts from each journal still showed inadequate 
abstract reporting, with fewer than 50% reporting the trial design, randomization, harms, 
and conclusions.78 Many abstract reporting differences were found between journals, 
suggesting that individual journal guidelines and house style have an impact on the 
adequacy of abstract reporting.78  
The most recent update using up to 100 RCTs published between 2011 and 2014 from 
five high impact, general medical journals (Annals IM, the BMJ, JAMA, the Lancet, and 
NEJM) still found an overall adherence of only 67%, ranging from 55% in the NEJM to 
78% in the Lancet.79 Though many journals have endorsed the CONSORT for Abstracts 
statement, full adherence to the guidelines is still lacking. Many other studies have 
focused on other medical areas to determine abstract adherence with similar conclusions 
(i.e. that abstract reporting needed to be improved).55,59,80–84 Discordance was also 
observed in 10% of RCTs focusing on lung cancer when comparing the conclusions in 
the abstracts to the full-text manuscript, with the majority of discrepancies arising from 
the experimental arm being described more favourably in the abstract than in the full-
text.58  
Abstract reporting in anesthesiology journals have been similarly unimpressive. 
Comparing pre-CONSORT abstracts in 2006 to post-CONSORT abstracts in 2009 for 
RCTs in four high-profile anesthesiology journals (Anaesthesia, A&A, Anesthesiology, 
and EJA), there were improvements in abstract reporting for the checklist items of 
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blinding, harms, appropriate title, and primary outcome – methods.85 However, overall, 
there were still on average, less than a third of the recommended CONSORT for 
Abstracts checklist items adequately reported in the abstract.85 Interestingly, RCT 
abstract adherence in the Korean Journal of Anesthesiology (KJA) increased from 41.7% 
in 2006 (pre-CONSORT) to 53.0% in 2012 (post-CONSORT), mainly due to 
improvements in the checklist items of trial design, randomization, blinding, and number 
randomized.86 No anesthesiology studies have reported on whether items not reported in 
the abstract were available in the full-text manuscript.  
For the top six general (non-pain-centric) anesthesiology journals as determined by 
impact factor, the instructions to authors do not specifically address adherence to the 
CONSORT for Abstracts statement, though Anaesthesia requires an unstructured abstract 
no more than 250 words,87 A&A requires a structured abstract no more than 400 words,88 
Anesthesiology requires a structured abstract no more than 250 words,44 BJA requires a 
structured abstract no more than 250 words,45 CJA requires a structured abstract no more 
than 250 words,49 and EJA requires a structured abstract no more than 300 words,46 
However, all six journals expect authors to be in compliance with the general CONSORT 
statement, which includes adhering to the CONSORT for Abstracts statement.44–46,49,87,88 
2.5 Sample Size  
2.5.1 Sample Size Calculation Assumptions 
The sample size is the number of participants included in the RCT and the sample size 
calculation is used to determine the minimum number of participants that need to be 
included in order to detect a clinically relevant treatment effect.89 RCTs with 
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inappropriate sample size calculations may be unethical as having a low sample size may 
prevent detecting differences between groups while having a high sample size may 
unnecessarily put participants at risk.90 While there is disagreement over whether 
underpowered trials are ethical, a priori sample size calculations are frequently used 
when planning RCTs.91 The CONSORT statement also recommends authors to report 
how sample size was determined, ideally with a high power to detect a statistically 
significant clinically relevant difference if one exists.38,71 
Sample size estimation methods vary based on the study design and outcome type so to 
stay consistent, sample size calculations in this thesis will be restricted to two arm, 
parallel, superiority RCTs with binary or continuous outcomes. To calculate the sample 
size, the expected outcomes for each group (which implies the clinically relevant effect 
size), the type I (α) error level, the type II (β) error or power level, and the standard 
deviation (only for continuous outcomes) are needed.38,92 Allowances made for attrition 
or non-compliance should also be included when appropriate.38,92 
For continuous outcomes, the standard deviations of the outcomes are also needed to 
determine the estimated variability of the data.93 Also known as the false-positive rate, 
the type I (α) error level is the probability of finding a difference between study arms 
when the difference does not actually exist.93 On the other hand, the type II (β) error level 
is also known as the false-negative rate and is the probability of failing to find a 
difference between study arms when a difference actually exists.93 In practice, this is 
usually reported as the power (1- β) or the true-positive rate, which means the probability 
of finding a difference between study arms if a difference actually exists.93 The type I (α) 
error level and the type II (β) error or power level are normally specified by the 
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investigators prior to the trial being conducted while the expected outcomes and 
variability for each group are estimated from previous studies or clinical expertise. 
Inappropriately estimated values for assumptions may result in underpowered or 
overpowered studies.94 
2.5.2 Quality of Sample Size Calculation 
The proportion of RCTs with the sample size reported has generally increased over the 
years.95 All two-arm, parallel group RCTs published in 2005 and 2006 for six high 
impact factor general medical journals (Annals IM, the BMJ, JAMA, the Lancet, NEJM, 
and PLoS Medicine) were assessed to determine the quality of their sample size 
calculations.96 Of included RCTs, 95% reported an a priori sample size calculation but 
only 53% reported all the required sample size calculation parameters.96 When comparing 
the sample size assumptions for the control group with the observed results, the absolute 
difference was greater than 30% for 31% of eligible RCTs and greater than 50% for 17% 
of eligible RCTs,96 suggesting either inappropriate estimations of sample size 
assumptions or a great degree of difficulty for accurate estimations of sample size 
assumptions.96 A study focusing on RCTs published in 2002 for four of those journals 
(Annals IM, JAMA, the Lancet, and NEJM) also found that 80% of the reported standard 
deviations were greater than the estimated standard deviations, resulting in 
underestimates of sample variability (and hence, sample size) for the majority of RCTs.97 
From 2000 to 2006, the percentage of anesthesiology RCTs reporting sample size 
estimates significantly increased from 52% to 86%.98 The quality of sample size 
calculations was also assessed for RCTs published in 2013 for ten anesthesiology 
journals (Acta, Anaesthesia, A&A, Anesthesiology, BJA, CJA, EJA, Journal of 
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Neurosurgical Anesthesiology, Pediatric Anesthesia, and RAPM).99 Similar to general 
medical journals, 92% of RCTs reported a sample size calculation, but surprisingly, 80% 
of these RCTs reported enough assumptions for sample size replication.99 Comparing 
replicated to reported sample sizes, 28.7% of RCTs exceeded a 10% difference.99 While 
the study did not report the percentage of RCTs with a greater than 10% difference 
between expected and reported outcomes, the overall median differences between 
expected and observed outcomes was 9% (IQR: −5 to 30%) for dichotomous outcomes 
and 9% (IQR: −30 to 30%) for continuous outcomes.99 
2.6 Impact of Funding Source on RCTs 
The percentage of industry funding in the United States for medical research rose from 
46% in 1994 to 58% in 2012, with the share of industry funding spent on phase three 
trials increasing by 36% from 2004 to 2011.100 Since the economic wellbeing of 
companies rely on favourable outcomes in the RCTs they fund, this may lead to biased 
research.101 
The impact that the funding source has on the outcomes of RCTs has been extensively 
studied, particularly the effect of industry funding. One systematic review identified all 
studies published up to 2002 that assessed the extent, impact, or management of financial 
relationships in trials.102 RCTs funded by industry were found to yield pro-industry 
conclusions (OR: 4.14; 95% CI: 2.72–6.32) when compared to non-industry-funded 
RCTs, even though industry-funded RCTs and non-industry-funded RCTs were found to 
be of similar methodological quality.102 A similar systematic review was performed the 
same year focusing on quantitative studies assessing the effect of pharmaceutical 
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company funding on methodological quality and outcomes.103 Clinical trials funded by 
pharmaceutical companies were associated with favouring the funders’ products and 
comparing the treatment to an inactive control.103 Half of the included studies indicated 
that industry- and non-industry-funded studies were of similar quality while the other half 
found that industry-funded studies clinical trials were of better quality.103 Another 
systematic review included studies published between 2003 and 2006, with 17 studies 
finding that industry-funded trials favoured the products of their funders and 2 studies 
finding no statistically significant association between funding source and outcome.104 A 
recent Cochrane systematic review in 2011 found convincing and consistent evidence for 
industry bias in pharmaceutical RCTs but insufficient evidence for medical device 
RCTs.105 Studies funded by industry had favourable efficacy results (risk ratio (RR): 
1.32; 95% CI: 1.21–1.44) and favourable conclusions (RR: 1.31; 95% CI: 1.20–1.44) 
more often than studies not funded by industry.106  
Four possible explanations for the positive outcomes of RCTs funded by industry are that 
industry only funds superior treatments, industry conducts poor quality trials, industry 
does not select an appropriate comparator, and industry contributes to publication bias by 
discontinuing or not publishing trials with non-favourable results (these factors are not 
mutually exclusive).103 However, the underlying principle for RCTs being conducted is 
uncertainty over whether the treatment or control are more beneficial,107 meaning that 
investigators would not be able know whether a treatment was superior until after the trial 
was performed. Studies have consistently shown that RCTs funded by industry are of 
similar or superior methodological quality to RCTs not funded by industry,104 suggesting 
that poor quality trials are not an adequate explanation unless other measures of quality 
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such as proper selection of controls are used. Publication bias is another likely 
explanation, but the increasing adoption of mandatory trial registration policies is aimed 
at alleviating this problem.24 
A study in 2015 found that, compared with cardiovascular RCTs funded by the federal 
government, those that were funded by industry were more likely to report positive or 
favourable outcomes and less likely to report unfavourable results, even when eliminating 
publication bias by only using data from a trials registry, clinicaltrials.gov. However, 
recent studies investigating the association between industry funding and trial quality in 
specific disciplines such as synbiotics/probiotics/prebiotics added to infant formula and 
rheumatoid arthritis have not found industry funding to be associated with a higher 
likelihood of positive outcomes,108,109 suggesting that industry has varying effects on 
RCTs in different specialties. More research concerning the effect of industry funding in 
anesthesiology RCTs is needed, including an explanation for the process through which 
industry can bias results. 
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3.1 Introduction 
Generally considered to be at the top of the evidence hierarchy for evaluating therapeutic 
interventions, randomized clinical trials (RCTs) and systematic reviews/meta-analyses of 
RCTs provide important evidence for clinical decision-making.1 While RCTs provide 
high quality evidence by minimizing selection bias through random allocation to groups, 
there are many other factors that may distort or bias the results. One tool used to improve 
RCT quality is trial registration, whose purpose is to reduce publication bias (i.e., not 
publishing studies deemed to be negative, uninteresting, or potentially damaging to the 
study’s sponsor) and selective outcome reporting (i.e., publishing only a subset of all 
outcomes measured, often favouring outcomes that are statistically significant).2 
Recognizing the importance of trial registration, the International Committee of Medical 
Journal Editors (ICMJE) mandates that all clinical trials commencing after July 1, 2005 
need to be registered in a public trials registry in order to be published in any of the 
ICMJE member journals.3  
Pre-specifying outcomes helps protect against data dredging and/or selective reporting, 
where only favourable outcomes are reported and unfavourable outcomes are obscured.4 
If authors elect to report different outcomes than the outcomes they registered, trial 
registries can also serve as an audit trail for the authors’ original intentions, allowing 
researchers to check published RCTs for potential outcome switching.5 Other researchers 
have reviewed the overall prevalence of outcome switching in the medical literature, 
finding a median discrepancy rate of 41% (interquartile range [IQR]: 33 – 48%) when 
comparing prospectively registered outcomes to reported outcomes.6 Though selective 
reporting has been studied in general and in specialty journals, only one study has 
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focused on the anesthesiology specialty, finding that 48% of registered trials had a major 
discrepancy when comparing the registry entry and the published manuscript.7 While De 
Oliveira et al. included RCTs published in one year (2013) from the top five general 
anesthesiology journals by impact factor,7 three of the included journals, Anesthesiology, 
Anaesthesia, and Anesthesia & Analgesia only mandate trial registration for clinical trials 
that begin patient enrollment after 2013,8 2014,9 and 2014,10 respectively. No study has 
yet performed a longitudinal analysis of outcome discrepancies in the anesthesia 
literature, nor has any study performed a detailed analysis of secondary outcome 
discrepancies.  
Our objective was to expand upon previous work by longitudinally examining the rate of 
adequate trial registration in the anesthesiology literature, focusing on RCTs published in 
2007, 2010, 2013, and 2015 for the top six general anesthesiology journals. We also 
planned to thoroughly investigate outcome discrepancies (i.e., differences between the 
outcomes registered and the outcomes reported) in both primary and secondary outcomes. 
3.2 Methods 
Publicly available, our study protocol was finalized in September 2016 and all analyses 
(except for the raw incidences of adequate trial registration) were conducted after this 
time.11  
Using the journals’ official websites, Tables of Contents were independently hand-
searched by two reviewers to identify eligible RCTs, with disagreements resolved by 
consensus. RCTs were only included if published in 2007, 2010, 2013, or 2015 in one of 
the top six general anesthesiology journals as determined by impact factor: Anaesthesia, 
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Anesthesia & Analgesia, Anesthesiology, British Journal of Anaesthesia, Canadian 
Journal of Anesthesia, and European Journal of Anaesthesiology.12 An electronic 
database was used to systematically screen and extract data from RCTs regarding general 
study characteristics and trial registration status. An RCT was defined as a prospective 
study assessing randomly allocated health care interventions in human participants and 
identified by authors clearly reporting random allocation of participants to the study arms 
through words like “random”, “randomized”, and “randomised” in the publication. 
Observational studies (e.g., case-control, or cohort studies), learning curve studies, 
cadaver studies, cost-effectiveness studies, dose-finding or dose-response studies which 
were not designed to test a clinical intervention, and diagnostic test accuracy studies were 
excluded. We also excluded meta-analyses, editorials, letters to the editor, narrative 
reviews, animal studies, manikin studies, simulation studies, duplicate reports, re-
analyses of previously published RCTs, and studies published in the correspondence 
section or in supplemental issues. If studies included two trials within one article, only 
data from the larger trial or phase was used.  
RCTs were considered adequately registered if the trial was registered in a publicly 
available trial registry prior to the first patient being enrolled and if the registry entry had 
a clearly defined primary outcome. The trial registration status was systematically 
ascertained through the use of full-text searching, trial registry searching, and emails to 
the corresponding author. Trial registry searching used the following registries: 
Clinicaltrials.gov, the International Standard Randomized Controlled Trial Number 
Register (ISRCTN), and the World Health Organization Clinical Trials Search Portal. If 
we could not positively determine a trial’s registration status by examining the full text of 
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the article or via registry searches, we sent up to two standardized emails to the 
corresponding author with a one-week gap between emails to determine the registration 
status. If the registration status of the trial still could not be determined after the two 
emails, the trial was considered to be unregistered. Trials registered using only the 
EudraCT database (https://www.clinicaltrialsregister.eu) were considered not registered 
since trials contained within the European Union Clinical Trials Registry (EUCTR) were 
not made publicly available until recently.13 
For each registered trial, the date of trial registration and first patient enrollment were 
collected to determine whether the trial was adequately registered. Trial registration date 
was defined as the date submitted for trial registration in the trials registry. If the date of 
first patient enrollment was not specified, the study start date was used instead. If the 
study start date specified only the month and year, trials were considered to be 
inadequately registered if the month occurred after the trial registration date. Trials 
registered after the first patient was enrolled or labelled as retrospectively registered in 
the trials registry were considered to be inadequately registered. An outcome was 
considered to be clearly defined if the outcome was clearly and unambiguously identified 
with a specific time frame in the trials registry. Only RCTs that were assessed to be 
adequately registered trials were further analyzed to determine the extent of outcome 
discrepancies.  
The journal, year, funding source, number of authors, sample size, and adequate 
registration status were also extracted from each included RCT to describe the general 
characteristics of the included RCTs. To address the primary objective, the number of 
outcomes reported in the trial registry, the number of outcomes reported in the published 
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article, and the presence of outcome discrepancies for included RCTs were also assessed. 
If the primary outcome was not explicitly described in the publication, the outcome used 
in the sample size calculation was considered to be the primary outcome. The number of 
participants per secondary outcome reported was calculated by dividing the sample size 
(number of participants randomized) by the number of secondary outcomes reported. Due 
to the number of RCTs included, RCTs were assigned to a single reviewer for data 
extraction and a second reviewer was consulted if a variable was unclear, with resolution 
by consensus.  
To provide more granularity, the type of outcome discrepancy was extracted with as 
much detail as possible. RCTs were considered to have a primary outcome discrepancy 
if: 
A) a registered primary outcome was not reported as a primary outcome (e.g., 24-
hr morphine consumption registered but not reported as a primary outcome) 
B) a reported primary outcome was not registered as a primary outcome (e.g., 6-
hr morphine consumption reported but not registered) 
C) the timing of a reported primary outcome was different from the timing of a 
registered primary outcome (e.g., the registered outcome was 30-day mortality 
but the reported outcome was 7-day mortality). 
A registered primary outcome that was not reported as a primary outcome might have 
been not reported at all or reported as a secondary outcome, while a reported primary 
outcome that was not registered as a primary outcome might have been not registered at 
all or registered as a secondary outcome. 
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Secondary outcomes were defined using a similar structure. A registered secondary 
outcome that was not reported as a secondary outcome might have been not reported or 
reported as a primary outcome while a reported secondary outcome that was not 
registered might have been not registered or registered as a primary outcome. Because of 
this hierarchical detail, some outcomes are identical but phrased differently (i.e., a 
registered primary outcome reported as a secondary outcome is the same as a reported 
secondary outcome registered as a primary outcome; a reported primary outcome 
registered as a secondary outcome is the same as a registered secondary outcome 
reported as a primary outcome).  
When an outcome discrepancy was identified, the reviewer determined the discrepancy to 
favour statistical significance if the reported outcome in question was statistically 
significant, as described by the authors. However, when a registered primary outcome 
was reported as a secondary outcome, the discrepancy was said to favour statistical 
significance if the registered primary outcome in question was not statistically significant. 
In discrepancies where a registered primary or secondary outcome was not reported at all, 
statistical significance favouring could not be determined. Outcomes were considered 
statistically significant if reported thus by the authors. Stata 14 statistical software 
(College Park, Texas) was used for all calculations and figures. For each of the four years 
measured, the number and percentage of RCTs with outcome discrepancies were 
summarized along with other descriptive statistics such as trial characteristics and 
number of outcomes. No inferential statistical tests were performed. 
52 
 
3.3 Results 
Of the 860 RCTs that fulfilled the inclusion/exclusion criteria, 556 were not registered 
and 202 were either registered after the first participant was enrolled or did not have a 
clear unambiguously-defined primary outcome in the registry entry, resulting in 102 
adequately registered trials assessed for the outcome discrepancy part of the study (Figure 
3-1). Table 3-1 describes the general characteristics for all of the included RCTs.  
 
Figure 3-1: Flowchart for inclusion of trials defined as adequately registered
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Table 3-1: Characteristics of trials 
Data presented are the number of trials / eligible trials (%) unless otherwise stated. Percentages may not sum to 100% due to rounding.  
a Adequate registration means that the trial was registered before the first participant was enrolled and that a primary outcome was clearly defined in the registry. 
b No trial registration was located during the systematic search using the full-text article, clinical trial registries, and corresponding author emails as described in 
the Methods of this manuscript 
Abbreviations: IQR, inter-quartile range. 
 
2007 
(n=316) 
2010 
(n=219) 
2013 
(n=170) 
2015 
(n=155) 
Journal     
Anaesthesia 45/316 (14%) 43/219 (20%) 28/170 (16%) 25/155 (16%) 
Anesthesia & Analgesia 97/316 (31%) 57/219 (26%) 37/170 (22%) 31/155 (20%) 
Anesthesiology 33/316 (10%) 23/219 (11%) 33/170 (19%) 27/155 (17%) 
British Journal of Anaesthesia 70/316 (22%) 36/219 (16%) 40/170 (24%) 27/155 (17%) 
Canadian Journal of Anesthesia 26/316 (8%) 16/219 (7%) 17/170 (10%) 20/155 (13%) 
European Journal of Anaesthesiology 45/316 (14%) 44/219 (20%) 15/170 (9%) 25/155 (16%) 
     
Number of authors, median (IQR) 6 (4 – 7) 6 (5 – 7) 6 (5 – 8) 6 (5 – 8) 
Trial sample size, median (IQR) 66 (40 – 110) 70 (44 – 120) 89 (56 – 150) 92 (57 – 150) 
     
Trials which were adequately registered a 2/316 (0.6%) 8/219 (4%) 33/170 (19%) 59/155 (38%) 
Registration identified in article 1/2 (50%) 8/8 (100%) 29/33 (88%) 54/59 (92%) 
Registration not identified in article 1/2 (50%) 0/8 (0%) 4/33 (12%) 5/59 (8%) 
     
Inadequately registered trials a 314/316 (99%) 211/219 (96%) 137/170 (81%) 96/155 (62%) 
No trial registration located b 285/314 (91%) 167/211 (79%) 73/137 (53%) 31/96 (32%) 
Registration occurred after the first participant was enrolled 22/314 (7%) 34/211 (16%) 45/137 (33%) 56/96 (58%) 
No or unclear primary outcome was specified in registry 0/314 (0%) 1/211 (0.5%) 8/137 (6%) 8/96 (8%) 
Registration occurred after the first participant was enrolled 
and no/unclear primary outcome was specified in the registry 
7/314 (2%) 9/211 (4%) 11/137 (8%) 1/96 (1%) 
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Figure 3-2 demonstrates a decreasing number of RCTs published in each journal over 
time, with only 155 RCTs identified in 2015 (compared to 316 in 2007). However, over 
time, an increasing proportion of these RCTs were adequately registered (Figure 3-3). 
This trend was consistent across all included journals, but overall, only 38% of RCTs 
were adequately registered in 2015. A detailed breakdown of why RCTs were considered 
inadequately registered is available in Table 3-1, with the reason “no trial registration 
located” decreasing over time and the reason “registration occurred after first patient 
being enrolled” correspondingly increasing over time. 
The majority of adequately registered trials had only one primary outcome, but almost 
one-third of RCTs had more than one (Table 3-2). There was a large discrepancy between 
the median [IQR] number of secondary outcomes registered (4 [1 - 8]) and the number of 
secondary outcomes reported (18 [10 – 29]) (Table 3-2). The median [IQR] number of 
study participants per secondary outcome reported declined from 2007 (23 [13 – 33]) to 
2015 (6 [2 – 11]) (Table 3-2).  
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Figure 3-2: Number of randomized clinical trials published by journal over time 
 
Figure 3-3: Percentage of adequately registered trials by journal over time 
An adequately registered trial was defined as being registered before the first participant was enrolled with 
a primary outcome clearly defined in the registry. 
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Table 3-2: Description of primary and secondary outcomes in adequately registered trials 
Data presented are the number of trials (%) unless otherwise stated. An outcome was considered to be clearly defined if the outcome was clearly and 
unambiguously identified with a specific time frame in the trials registry. By definition, all primary outcomes for the adequately registered trials in this Table 
were clearly defined. 
Abbreviations: IQR, interquartile range. 
 
2007 
(n=2) 
2010 
(n=8) 
2013 
(n=33) 
2015 
(n=59) 
Registered outcomes in trial registry     
Only one primary outcome registered in trial registry 1 (50%) 4 (50%) 25 (76%) 42 (71%) 
More than one primary outcome registered in trial registry 1 (50%) 4 (50%) 8 (24%) 17 (29%) 
Number of secondary outcomes registered in trial registry, median (IQR) 2.5 (0 – 5) 7.5 (1.5 – 12.5) 3 (1 – 7) 4 (2 – 8) 
Number of trials with at least one unclear secondary outcome registered 
in trial registry 
0 (0%) 3 (38%) 10 (30%) 16 (27%) 
     
Reported outcomes in published article     
One primary outcome reported in published article 2 (100%) 4 (50%) 27 (82%) 42 (71%) 
More than one primary outcome reported in published article 0 (0%) 4 (50%) 6 (18%) 17 (29%) 
Number of secondary outcomes reported in published article, median 
(IQR) 
5.5 (5 – 6) 19.5 (7.5 – 29.5) 12 (8 – 26) 19 (11 – 36) 
Number of trials with at least one unclear secondary outcome reported in 
published article 
0 (0%) 1 (13%) 4 (12%) 2 (3%) 
     
Number of participants per secondary outcome reported, median (IQR) 23 (13 – 33) 4 (3 – 16) 6 (3 – 14) 6 (2 – 11) 
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Table 3-3 presents the data on outcome discrepancies, showing that 92% of adequately 
registered trials in 2015 had at least one primary or secondary outcome discrepancy, with 
59% of them favouring statistical significance. Results for RCTs published in 2007 are 
difficult to interpret due to the small number of adequately registered trials, but RCTs 
published in 2013 and 2015 had a slightly smaller percentage of RCTs with at least one 
primary or secondary outcome discrepancy compared to RCTs published in 2007 and 
2010. When stratifying by type of outcome discrepancy, adequately registered trials 
published in 2007 and 2010 had a higher percentage of having at least one primary 
outcome discrepancy but the trend is reversed for secondary discrepancies, with 
adequately registered trials published in 2013 and 2015 having a higher percentage of 
having at least one secondary outcome discrepancy. Correspondingly, in 2015, many of 
the outcome discrepancies were related to issues with the secondary outcome, with 90% 
of adequately registered trials having at least one secondary outcome discrepancy. In 
2015, 86% of adequately registered trials had at least one reported secondary outcome not 
registered, accounting for most of the secondary outcome discrepancies observed. 
Overall, the outcome discrepancies with the lowest percentages were having at least one 
registered secondary outcome reported as a primary outcome (6%) and having at least 
one registered primary outcome not reported at all (11%). The number and percentage of 
outcome discrepancies stratified by journal can be found in Appendix C. 
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Table 3-3: Differences between outcomes when comparing the published trial to the trial registry among adequately registered 
trials 
A: Data presented are the number of trials (%). All percentages are column percentages with the denominator set to the total number of trials published. 
B: Data presented are the proportion of trials where the identified discrepancy favoured statistical significance (see article text for details).  
All uses of ‘registered’ pertain to the outcome as registered in the trial registry and all uses of ‘reported’ pertain to the outcome as reported in the published 
manuscript. If there are one or more occurrences of the discrepancy in a trial, the trial will be counted as having the described discrepancy. Subcategories are not 
mutually exclusive so if individual studies have more than one discrepancy, the sum of the subcategories will be larger than the parent category.  
“N/A” represents values where it could not be determined whether the discrepancy favoured statistical significance: either when the discrepancy involved an 
outcome not being reported or when there were no studies with the discrepancy. 
 
a Trials with at least one discrepancy between the primary or secondary outcomes reported in the published article and those registered in the trial registry. 
b Trials with at least one discrepancy between the primary outcome reported in the published article and that registered in the trial registry. 
c Trials with at least one discrepancy among any of the secondary outcomes reported in the published article and those registered in the trial registry. 
* While the wording is slightly different, both rows are equivalent, as both show a registered primary outcome being reported as a secondary outcome.  
** While the wording is slightly different, both rows are equivalent, as both show a registered secondary outcome being reported as a primary outcome. 
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2007 
(n=2) 
2010 
(n=8) 
2013 
(n=33) 
2015 
(n=59) 
 A B A B A B A B 
Trials with any primary or secondary outcome discrepancy a 2 (100%) 1.00 8 (100%) 0.50 30 (91%) 0.63 54 (92%) 0.59 
         
Trials with primary outcome discrepancies b 1 (50%) 1.00 6 (75%) 0.67 14 (42%) 0.79 25 (42%) 0.56 
Registered primary outcome not reported as primary outcome  1 (50%) 0.00 3 (38%) 0.33 7 (21%) 0.43 14 (24%) 0.00 
Registered primary outcome not reported at all 1 (50%) N/A 1 (13%) N/A 3 (9%) N/A 6 (10%) N/A 
Registered primary outcome reported as secondary outcome * 0 (0%) N/A 2 (25%) 0.50 5 (15%) 0.60 9 (15%) 0.00 
Reported primary outcome not registered as primary outcome 1 (50%) 1.00 4 (50%) 0.75 7 (21%) 0.86 17 (29%) 0.71 
Reported primary outcome not registered 1 (50%) 1.00 4 (50%) 0.75 5 (15%) 0.80 13 (22%) 0.62 
Reported primary outcome registered as secondary outcome ** 0 (0%) N/A 0 (0%) N/A 2 (6%) 1.00 4 (7%) 1.00 
Timing of reported primary outcome different from primary outcome 
registered 
0 (0%) N/A 0 (0%) N/A 5 (15%) 0.60 8 (14%) 0.38 
         
Trials with secondary outcome discrepancies c 1 (50%) 1.00 7 (88%) 0.43 30 (91%) 0.50 53 (90%) 0.53 
Registered secondary outcome not reported as secondary outcome 0 (0%) N/A 2 (25%) 0 9 (27%) 0.22 17 (29%) 0.24 
Registered secondary outcome not reported at all 0 (0%) N/A 2 (25%) N/A 7 (21%) N/A 13 (22%) N/A 
Registered secondary outcome reported as primary outcome ** 0 (0%) N/A 0 (0%) N/A 2 (6%) 1.00 4 (7%) 1.00 
Reported secondary outcome not registered as secondary outcome  1 (50%) 1.00 7 (88%) 0.43 26 (79%) 0.50 51 (86%) 0.45 
Reported secondary outcome not registered 1 (50%) 1.00 7 (88%) 0.29 25 (76%) 0.44 51 (86%) 0.45 
Reported secondary outcome registered as primary outcome * 0 (0%) N/A 2 (25%) 0.50 5 (15%) 0.60 9 (15%) 0.00 
Timing of reported secondary outcome different from secondary outcome 
registered 
0 (0%) N/A 1 (13%) 0.00 10 (30%) 0.30 9 (15%) 0.33 
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3.4 Discussion 
We found at least two major problems in the anesthesia literature — low rates of 
adequate RCT registration and high rates of discrepancies between the outcomes 
registered at a trials registry and the outcomes actually reported in a journal. While the 
proportion of adequately registered trials trended upward for all six journals over time, 
the overall percentage of 38% in 2015 is still inadequate. However, not all journals had 
the same proportion of adequately registered trials. 
Although transparency of research conduct is the primary reason for an investigator to 
register their RCT, for some researchers, journal-specific policies may have impacted 
their registration decision. Anesthesiology, British Journal of Anaesthesia (BJA), and 
European Journal of Anaesthesiology (EJA) described their mandatory trial registration 
policy in their Instructions to Authors sections starting in 2013,14 2009,15 and 2015,16 
respectively. Anaesthesia and Anesthesia & Analgesia (A&A) both confirmed a 
mandatory trial registration policy starting in 2014 after emails to the editorial office,9,10 
while the Canadian Journal of Anesthesia (CJA) still only strongly recommends trial 
registration in its Instructions to Authors section.17 Interestingly, despite the lack of a 
policy mandating RCT registration, the CJA did not have the lowest proportions of 
adequately registered trials — indicating that written journal policy is not necessarily the 
primary determinant of acceptance of inadequately registered RCTs.  
Journals requiring RCTs to be registered in a public trials registry should, by definition, 
have a near 100% proportion of adequately registered trials but the results of this study 
demonstrate otherwise. We suspect this is because not all of the details of trial 
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registration are systematically being checked by journals — particularly whether trials 
are registered before the first study participant is enrolled. Also known as retrospective 
registration, registering trials after patient enrollment may not help to reduce publication 
and selective reporting bias.18 The largest problem with retrospective registration is that it 
makes it appear as though there is complete alignment between registration and reporting, 
giving the impression of complying with a journal’s registration policy without actually 
doing so. We therefore recommend heightened vigilance at all journals to recognize this 
problem. 
We compared the results of our study with the De Oliveira et al. study that also examined 
the proportion of adequately registered trials in Anaesthesia, Anesthesia & Analgesia, 
Anesthesiology, and British Journal of Anaesthesia in 2013.7 Our study expanded on this 
work in two major ways: first, by examining only adequately registered RCTs (defined as 
a trial which was registered in a publicly available trial registry prior to the first patient 
being enrolled and a registry entry containing a clearly defined primary outcome), and 
second, by performing a longitudinal examination over four different years rather than 
just a single year. Overall, the De Oliveira et al. study found that 35% of published 
clinical trials in anesthesia literature were prospectively registered,7 about two times 
larger than the 19% we found (for those journals in 2013) in our study. For each 
individual journal, we found fewer RCTs published and fewer adequately registered 
RCTs than did De Oliveira et al.7 This difference is likely due to different 
inclusion/exclusion criteria since De Oliveira et al. identified trials through a PubMed 
search7 while we used hand-searching of each journal’s Table of Contents and inclusion 
criteria that were more stringent (e.g., exclusion of dose-finding or dose-response studies 
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which were not designed to test a clinical intervention). As noted above, our stricter 
definition of what constituted an adequately registered RCT may have also contributed to 
the discrepancy since the De Oliveira et al. study only required adequately registered 
trials to be prospectively registered.7 
Even within adequately registered RCTs, significant discrepancies between registered 
and published outcomes can affect the quality of published trials.2 In some cases, this 
outcome switching is warranted and authors should explain the reasons for the changes, 
but outcome switching may also be used to spin and distort the data to have more 
favourable conclusions.6,19 While the number of adequately registered trials with at least 
one primary or secondary outcome discrepancy in 2015 showed a decrease from 2007 
and 2010, 92% of adequately registered trials published in 2015 still had at least one 
primary or secondary outcome discrepancy. For adequately registered trials published in 
2015, 90% of trials had at least one secondary outcome discrepancy, with most of these 
discrepancies due to the reported secondary outcome not being registered. Historically, 
serendipitous findings (which are often secondary outcomes) have been responsible for 
many important scientific discoveries, so researchers should feel free to report these 
unexpected findings. However, to maintain the important scientific tradition of being 
open and transparent about a study’s methods, these unregistered outcomes should be 
labelled as “post-hoc” or “exploratory”. 
The Centre for Evidence-Based Medicine Outcome Monitoring (COMPare) project also 
found that in the top five medical journals, each trial silently added, on average, 5.3 new 
outcomes.5 In the current study, 42% of RCTs published in 2015 had at least one primary 
outcome discrepancy, which is concerning since the primary outcome is the objective of 
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the trial and distortion of the primary outcome will affect every aspect of the trial. No 
specific type of primary outcome discrepancy accounted for most of the discrepancies, 
but when the reported primary outcome was not registered as the primary outcome, there 
was a higher chance that the discrepancy favoured statistical significance. While a 
systematic review of all studies assessing outcome discrepancies found a median 
percentage of primary outcome discrepancies of 32% (IQR: 25% – 45%) and a median 
percentage of secondary outcome discrepancies of 54% (IQR: 33% – 68%),6 the current 
study found 45% and 89%, respectively, suggesting either that RCTs in anesthesiology 
journals may have more outcome discrepancies than general and other specialty journals 
or that different studies may use varying methodologies. Comparing again to the De 
Oliveira et al. study which focused on anesthesiology journals, the authors found that 
43% of trials had a primary outcome discrepancy and 79% of trials had a secondary 
outcome discrepancy,7 similar to the results of our study.  
With each successive year, more adequately registered RCTs have registered and 
reported more than one primary outcome. The median number of registered and reported 
secondary outcomes fluctuates between years but the number of reported secondary 
outcomes is always higher than the number of registered secondary outcomes. This 
corresponds to the high percentage of secondary outcome discrepancies observed, 
especially with reported secondary outcomes that were not registered. To maintain the 
effectiveness of trial registration, investigators should ensure that all outcomes are 
included in the registry entry, even secondary outcomes. The number of participants 
divided by the number of secondary outcomes reported is consistent around 6 except in 
2007, though this may be influenced by the low number of adequately registered trials 
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published in 2007. When more variables are measured without increasing the sample 
size, there is a higher probability of getting a statistically significant result by chance 
alone.20 There is considerable variation in the number of secondary outcomes reported 
but investigators should avoid measuring too many secondary outcomes if the sample 
size is small. It is concerning that, in 2015, 25% of adequately registered RCTs had two 
or fewer study participants per secondary outcome analyzed. 
An unexpected finding of our study (an unplanned, post-hoc secondary outcome) that is 
deeply concerning is the large decline in the absolute number of RCTs being reported in 
the anesthesia literature. Potential reasons for this include a lack of grant funding to 
support research, the ever-increasing and frustrating bureaucratic “red tape” involved in 
conducting research, a shift in RCT publication from the highest impact factor journals to 
lower impact factor journals, or researchers eschewing randomized study designs in 
favour of observational designs (which may also involve less regulation and be less 
onerous to conduct). 
Limitations of our study include the arbitrary selection of years examined, the number of 
reviewers, the exclusion of EUCTR registered RCTs, and the presence of non-responding 
corresponding authors. In this study, only the years of 2007, 2010, 2013, and 2015 were 
included with no data pertaining to RCTs published in unmeasured years. While two 
reviewers were used to screen for eligible RCTs, only one reviewer extracted data from 
each RCT, potentially increasing the amount of error. To reduce this error, reviewers 
were trained prior to data extraction with the same guidelines and a second reviewer was 
consulted if any variable was unclear.  
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Another limitation was that all RCTs registered in the EUCTR were considered to be 
unregistered, and subsequently excluded from analyses concerning adequately registered 
RCTs. Since the EUCTR was only available for public access starting in 2011,13 RCTs in 
2007 and 2010 using that registry would not have been publicly available. To maintain 
consistency, RCTs in subsequent years were also considered to be unregistered as many 
studies published in 2013 and 2015 would likely have commenced their trial planning 
and/or recruitment stages before 2011. For this reason, approximately six and four RCTs 
were excluded in 2013 and 2015, respectively. Since articles with authors that were 
unable to be contacted after two attempts were considered unregistered, the proportion of 
adequately registered trials may have been underestimated if nonresponding authors had 
actually registered their trials. There is potential for bias as authors with recently 
published studies may be more easily contacted. However, there is only a small chance of 
this misclassification as publications and clinical trial registries were also searched for 
relevant registration information. 
In conclusion, an alarming proportion of published randomized clinical trials in the 
anesthesia literature are still inadequately registered despite long-standing international 
guidelines recommending trial registration. We suggest that journal editors need to be 
more vigilant when enforcing their registration policies. Peer reviewers should also 
consider it a responsibility to reconcile the registered and published outcomes when 
reviewing manuscripts. Unfortunately, even amongst adequately registered trials, 
important discrepancies still sometimes exist between the registered outcomes and the 
reported outcomes. Primary outcome switching can systematically distort the anesthesia 
literature and potentially negatively affect patient care if clinicians base their practice on 
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distorted evidence. Continued longitudinal research of the incidence and severity of these 
problems is warranted. 
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4.1 Introduction 
Randomized clinical trials (RCTs) are generally considered to be at the top of the 
evidence hierarchy when determining the benefits and harms of therapeutic 
interventions.1 Abstracts are concise summaries of the entire RCT and are often used by 
readers to determine whether reading the full-text manuscript is warranted.2 Interestingly, 
the BMJ found that it was valid for editors to reject a manuscript submission based only 
on reading the abstract, with an estimated 15-25% of papers rejected on that initial 
abstract read-through.3 In the study, editors would read the abstract only, record their 
initial decision (or inability to make a decision), and then read the entire manuscript, 
processing it as usual.3 For manuscripts that the BMJ editors determined could be rejected 
after only reading the abstract, the final decision after the entire process was still 
rejection.3 Abstracts are also important tools for clinical decision-making because there 
may be financial, information technology, time, or language barriers that prevent or 
reduce access to all full-text manuscripts.2,4,5 Indeed, just over 50% of studies published 
in 2009 and indexed on PubMed were found to be open access, leaving almost half of the 
studies in the biomedical field with the full-text only accessible by subscription.6 
Together, these factors imply that many clinicians may use the abstracts of clinical trials 
to guide clinical decision-making without ever having read the full text of a particular 
article. Therefore, it is clear that the quality of abstract reporting is of paramount 
importance. 
To improve the quality of reporting RCT abstracts, an extension of the Consolidated 
Standards of Reporting Trials (CONSORT) statement was developed and published in 
2008.7,8 This CONSORT for Abstracts statement specified a minimum set of criteria that 
71 
 
authors should include in the abstract of a RCT, ensuring that readers have the necessary 
detail and clarity to assess a RCT’s validity and applicability.7 
A study comparing 2006 (pre-CONSORT) and 2009 (post-CONSORT) abstracts 
published in four high profile anesthesiology journals found some improvements in areas 
such as blinding and harms, with an overall 2.5% increase in the percentage of 
recommended criteria included.9 However, on average, there were still fewer than a third 
of the checklist items reported in each RCT published in 2009.9 For RCTs published in 
four high-impact general medical journals in 2010, some items were adequately reported 
while some items such as trial design, randomization, blinding, harms, conclusions, and 
funding were reported in fewer than 50% of RCTs.10  
No studies in the anesthesiology literature have examined whether the items omitted from 
the abstract are present in the body of the manuscript. If the items are not reported in both 
the abstract and the full-text, the underlying problem may be inadequate trial reporting 
and not inadequate abstract reporting. If items are not reported in the abstract but are 
present in the full-text, the CONSORT for Abstracts guidelines are not being adhered to 
even though the information is available in the full-text. This lack of adherence may 
intentionally or unintentionally cause abstract readers to have a distorted impression of 
the RCT’s validity or applicability. “Spin” and misrepresentation of the salient trial 
details in the abstract have an impact on clinicians’ interpretations of an RCT, where a 
small modification in an abstract’s focus can make clinicians more likely to consider a 
treatment beneficial despite the primary outcome being statistically nonsignificant.11  
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The objective of this study was to determine the degree of adherence to CONSORT’s 
abstract reporting guidelines for RCTs published in anesthesiology journals. For checklist 
items not reported in the abstract, this study also identified whether they were reported in 
the full-text manuscript to determine the potential for inadequate abstract reporting 
distorting or “spinning” a RCT’s findings. The top six general (non-pain-centric) 
anesthesiology journals as determined by impact factor were included to further examine 
between-journal differences. Our hypothesis was that newer trials would adhere to the 
CONSORT for Abstracts guidelines more completely compared to older trials; since 
journals specify different formats and restrictions for reporting abstracts, they would also 
be an important predictor of adherence. This study updated the literature on 
anesthesiology RCT abstract reporting by using RCTs published in 2016 and comparing 
them with RCTs published in 2010 to determine whether there was an improvement over 
time. 
4.2 Methods 
An electronic database was set up to identify and retrieve all RCTs published in the top 
six general anesthesiology journals as determined by impact factor in 2016: Anaesthesia, 
Anesthesia & Analgesia (A&A), Anesthesiology, British Journal of Anaesthesia (BJA), 
Canadian Journal of Anesthesia (CJA), and European Journal of Anaesthesiology 
(EJA).12 Since the CONSORT for Abstracts statement was published in 2008,7,8 2010 was 
selected as the first year for analysis. To show a longitudinal trend and provide the most 
current results, RCTs were only included if published in 2010 or 2016.  
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Using the websites for each included journal, the Table of Contents’ for each month, 
excluding supplemental issues, were independently hand-searched by two reviewers to 
identify eligible RCTs. Disagreements were assessed by a third reviewer with a decision 
made through consensus by all three reviewers. A RCT was defined as a prospective 
study assessing randomly allocated health care interventions in human participants, with 
random allocation of participants to study arms clearly reported (i.e. the use of the words 
“random”, “randomized”, or “randomised”). As a result, observational studies (e.g. case-
control or cohort studies), learning curve studies, cadaver studies, cost-effectiveness 
studies, dose-finding or dose-response studies which were not designed to test a clinical 
intervention, diagnostic test accuracy studies, meta-analyses, editorials, narrative reviews, 
animal studies, manikin studies, and re-analyses of previously published studies were all 
excluded. RCTs published in the correspondence or letters to the editor sections were also 
excluded. If two phases were reported in one study, the phase with the highest number of 
participants was used for data extraction. RCTs identified as meeting the 
inclusion/exclusion criteria were retrieved and stored in a prospectively created electronic 
database. More details regarding methodology can be found in our publicly available 
study protocol.13  
Data extraction was performed for all RCTs using the created electronic database. Data 
extraction for included RCTs were performed by one of four reviewers. All reviewers 
were trained together to ensure consistency of data extraction. Ambiguous data points 
were assessed by a second reviewer with a decision made through consensus. General 
study characteristics were extracted including journal, year, multicentricity, study design, 
sample size, and trial registration status. The number randomized was used for the sample 
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size. Adequate trial registration was defined as the trial being registered in a publicly 
available trial registry before the first participant was enrolled with a clearly defined 
primary outcome. To identify a RCT’s registration status, the full-text was first searched 
for trial registration information. If none was located, searches were performed at the 
following websites: www.clinicaltrials.gov, the International Standard Randomized 
Controlled Trial Number Register (ISRCTN), and the World Health Organization (WHO) 
Clinical Trials Search Portal (which simultaneously searches 16 clinical trial registries). 
If no information was found during the trial registry search, two attempts (separated by a 
week) were made to contact the corresponding author using a standardized email asking 
whether or not the trial was registered, what the registration number was, and which 
registry was used (Appendix B). The RCT was assumed to be not registered if no 
registration information was identified using the steps above. Trials that were only 
registered at EudraCT (https://www.clinicaltrialsregister.eu) were considered not 
adequately registered since the information contained in that database was not publicly 
available until the release of the European Union Clinical Trials Register (EUCTR) in 
2011.14 
Adequate trial registration was determined using the date of trial registration and date of 
first patient enrollment. However, if the trial registry indicated that a RCT was 
retrospectively registered, this was accepted at face value. If the trial registration date 
occurred before the first patient enrollment date, the RCT was considered to be 
adequately registered. The date of trial registration was determined by the date submitted 
for trial registration as specified in the trial registry. The date of first patient enrollment 
was determined by the date specified in the full-text publication. If no date was provided 
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in the publication, the study start date as specified in the clinical trial registry was used 
instead. If no date was provided in the publication or trial registry, the RCT was 
considered inadequately registered. For study start dates that only included the month and 
year, RCTs were considered to be adequately registered if the month was during or 
before the trial registration date. 
Since no validated scoring system for abstract quality exists, the 16 checklist items from 
the CONSORT for Abstracts statement7,8 were used to create a convenience score as a 
proxy for RCT abstract reporting quality. A brief description of each item was adapted 
from the CONSORT for Abstracts statement explanations and presented alongside each 
checklist item during data extraction to improve quality (Appendix D). Each criterion 
was measured as being reported in abstract, not reported in abstract but reported in full-
text manuscript, or not reported in abstract or full-text manuscript, then used to calculate 
summary measures such as number of trials with the checklist item reported and the 
number of trials with the checklist item reported in the full-text only. An overall score 
was calculated by counting the number of criteria reported in each RCT’s abstract. Since 
the CONSORT for Abstracts statement only focuses on primary outcomes, the number of 
secondary outcomes reported in the abstract and the number of statistically significant 
secondary outcomes reported in the abstract were also extracted to calculate a percentage 
of secondary outcomes reported in the abstract that were statistically significant. 
Descriptive statistics were used to present the raw number and percentage of checklist 
items reported for included RCTs. To assess differences between years, the Pearson chi-
square test was used for categorical variables and the Wilcoxon rank-sum (Mann-
Whitney) test was used for continuous variables. The Kruskal-Wallis test was used to 
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assess differences between journals stratified for each year of publication. To improve 
clarity in the results, the overall CONSORT for Abstracts score is reported as the 
abstract-only score and the number of full-text only (reported in the manuscript but not in 
the abstract) items is reported as the full-text-only score. Stata 13 statistical software 
(StataCorp LLC, College Park, Texas) was used for all analyses. P<0.05 was considered 
statistically significant.   
4.3 Results 
Table 4-1 describes the general characteristics for the 395 included RCTs, with 219 
published in 2010 and 176 published in 2016. While the total number of RCTs decreased 
from 2010 to 2016, Anesthesiology and CJA had an absolute increase in the number of 
included RCTs. Most RCTs were conducted at a single-centre and had a parallel group 
superiority design. From 2010 to 2016, the number of single-centre RCTs decreased from 
94% to 86% (Pearson chi-square: p=0.02), the number of adequately registered RCTs 
increased from 4% to 39% (Pearson chi-square: p<0.001), and the median sample size 
increased from 68 to 86 (Wilcoxon rank-sum: p=0.03).  
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Table 4-1:  Characteristics of RCTs included for analysis 
Data presented are the number of trials (%) unless otherwise stated. Percentages may not add up to 100% 
due to rounding. IQR means interquartile range.  
1 Multi-centre is defined as participants recruited from more than one institution or clinic  
2 Adequate registration is defined as the trial being registered before the first participant was enrolled and 
that a primary outcome was clearly defined in the registry. 
 2010 
(n=219) 
2016 
(n=176) 
Journal   
Anaesthesia 43 (20%) 38 (22%) 
Anesthesia & Analgesia 57 (26%) 33 (19%) 
Anesthesiology 23 (11%) 26 (15%) 
British Journal of Anaesthesia 36 (16%) 34 (19%) 
Canadian Journal of Anesthesia 16 (7%) 21 (12%) 
European Journal of Anaesthesiology 44 (20%) 24 (14%) 
   
Multicentricity1   
Single-centre  205 (94%) 152 (86%) 
Multi-centre 14 (6%) 24 (14%) 
   
Study Design   
Parallel (superiority) 188 (86%) 138 (78%) 
Parallel (non-inferiority/equivalence) 8 (4%) 16 (9%) 
Crossover 15 (7%) 19 (11%) 
Other 8 (4%) 3 (2%) 
   
Trial Registration2   
Adequately Registered 8 (4%) 68 (39%) 
Inadequately Registered 211 (96%) 108 (61%) 
   
Median Sample Size (IQR) 68 (44–120) 86 (50–139) 
 
While the overall CONSORT for Abstracts abstract-only score increased from 2010 to 
2016 for each journal, the median score was below 10 (out of a possible 16) for every 
journal (Figure 4-1) in both years analyzed. The distributions of the abstract-only scores 
were statistically significantly different between years; the median abstract-only score 
increased from 4 points [interquartile range (IQR): 3 to 5] in 2010 to 6 points [IQR: 5 to 
8] in 2016 (Wilcoxon rank-sum: p<0.0001) (Figure 4-2; Table 4-2). When analyses were 
stratified by year, there was a statistically significant difference for the abstract-only 
score between the different journals of publication (Kruskal-Wallis: p<0.0001 for 2010 
and p<0.0001 for 2016) (Figure 4-1).  
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Figure 4-1: Distribution of overall CONSORT for Abstracts abstract-only score by 
journal over time  
White line represents median; box represents 25th and 75th percentiles; each whisker represents 1.5 times 
interquartile range; dots represent outside values 
 
Figure 4-2: Distributions of overall CONSORT for Abstracts abstract-only score in 
2010 and 2016 
Wilcoxon Rank-Sum test for difference in distribution: p<0.0001
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Table 4-2:  Adherence to CONSORT-Abstract reporting items in RCTs 
(A) Number of trials (%) with the checklist item reported  
(B) Of trials with the checklist item not reported in the abstract, the number (%) of these trials with the 
checklist item reported in the manuscript 
1 Abstract-only score: Number of CONSORT for Abstracts criteria reported in the abstract  
(Wilcoxon rank-sum test for difference in distribution between years: p<0.0001) 
2 Full-text-only score: Number of CONSORT for Abstracts criteria reported only in the full-text manuscript  
(Wilcoxon rank-sum test for difference in distribution between years: p=0.02) 
 2010 2016 
 A  
(n=219) 
B A 
(n=176) 
B 
Title      
 “Randomized” in title 56 (26%) N/A 131 (74%) N/A 
 “Randomized” in abstract 145 (66%) 18/18 (100%) 40 (23%) 5/5 (100%) 
Trial Design 45 (21%) 128/174 (74%) 57 (32%) 81/119 (68%) 
Methods     
Participants 10 (5%) 91/209 (44%) 74 (42%) 99/102 (97%) 
Interventions 156 (71%) 62/63 (98%) 106 (60%) 70/70 (100%) 
Objective 54 (25%) 70/165 (42%) 63 (36%) 86/113 (76%) 
Outcome 38 (17%) 74/181 (41%) 101 (57%) 49/75 (65%) 
Randomization 3 (1%) 150/216 (69%) 3 (2%) 152/173 (88%) 
Blinding (masking) 82 (37%) 107/137 (78%) 66 (38%) 93/110 (85%) 
Results     
Numbers randomized 81 (37%) 101/138 (73%) 74 (42%) 102/102 (100%) 
Recruitment 5 (2%) 182/214 (85%) 33 (19%) 140/143 (98%) 
Numbers analyzed 30 (14%) 169/189 (89%) 37 (21%) 139/139 (100%) 
Outcome 13 (6%) 30/206 (15%) 71 (40%) 25/105 (24%) 
Harms 108 (49%) 75/111 (68%) 104 (59%) 46/72 (64%) 
Conclusions 203 (93%) 11/16 (69%) 161 (91%) 14/15 (93%) 
Trial registration 13 (6%) 43/206 (21%) 70 (40%) 75/106 (71%) 
Funding 0 (0%) 153/219 (70%) 0 (0%) 168/176 (95%) 
Median Score (IQR) 4 (3–5)1  7 (6–9)2 6 (5–8)1 8 (7–9)2 
 
The median full-text-only score increased from 7 points [IQR: 6 to 9] in 2010 to 8 points 
[IQR: 7 to 9] in 2016 (Wilcoxon rank-sum: p=0.02) (Table 4-2). There was also a 
statistically significant difference for the full-text-only score between the different 
journals of publication (Kruskal-Wallis: p<0.0001 for 2010 and p<0.0001 for 2016). A 
breakdown of the number of trials with the checklist item reported in the abstract, not 
reported in abstract but reported in manuscript, and not reported in abstract or manuscript 
is presented in Table 4-2. Appendix E presents the same information for RCTs published 
in 2016 stratified by each journal. Without adjusting for multiple comparisons, Pearson's 
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chi-squared tests for differences between journals suggest that the journal had a 
statistically significant effect on adherence to the CONSORT for Abstracts guidelines for 
every criterion except for randomization, numbers randomized, and numbers analyzed 
(Appendix E). The mean percentage of statistically significant secondary outcomes in the 
abstract decreased slightly from 60% in 2010 to 55% in 2016 though the standard 
deviations in both years were large (Table 4-3). 
Table 4-3: Characteristics of secondary outcomes reported in the abstract 
IQR means interquartile range and SD means standard deviation 
1 Using the secondary outcomes reported in the abstract for each trial, the number of statistically significant 
secondary outcomes was divided by the number of secondary outcomes to get the percentage. The mean 
and standard deviation were calculated using the percentages calculated for each trial. 
 2010 2016 
Median number (IQR) of secondary outcomes reported in abstract 3 (1–4) 3 (2–4) 
   
Median number (IQR) of statistically significant secondary 
outcomes reported in abstract 
1 (0–3) 1 (0–2) 
   
Mean percentage (SD) of secondary outcomes reported in the 
abstract that were statistically significant1 
60% (37%) 55% (39%) 
 
4.4 Discussion 
The results of this study suggest that many anesthesiology RCTs are not following the 
CONSORT for Abstracts guidelines when publishing their final manuscripts. A previous 
study examining adherence to the CONSORT for Abstracts guidelines for four general 
anesthesiology journals found the mean proportion of items reported to be 26.6% [95% 
CI: 25.5 to 28.0] in 2006 and 29.0% [95% CI: 27.2 to 30.2] in 2009.9 The median number 
of items reported in this study was four in 2010 and six in 2016, which corresponds to 
25% and 38%, respectively. Since the CONSORT for Abstracts guidelines were 
published in 2008, this increase may be due to more authors and editors being aware of 
them. However, there are still many criteria that are consistently not being reported by 
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authors. Since the results suggest that there are differences between journals, journal-
specific policies may have some effect. Indeed, they may be the principal driver of the 
differences observed.  
For each of the six included anesthesiology journals, the instructions to authors do not 
specifically address adherence to the CONSORT for Abstracts statement. However, all 
six journals require or recommend compliance with the general CONSORT guidelines, 
which includes adhering to the CONSORT for Abstracts guidelines.15–20 In terms of 
abstract-specific instructions, Anaesthesia requires an unstructured abstract no more than 
250 words,15 Anesthesia & Analgesia requires a structured abstract no more than 400 
words,19 Anesthesiology requires a structured abstract no more than 250 words,16 British 
Journal of Anaesthesia requires a structured abstract no more than 250 words,17 
Canadian Journal of Anesthesia requires a structured abstract no more than 250 words,18 
and European Journal of Anaesthesiology requires a structured abstract no more than 300 
words.20 Though there are strict word limits that authors cannot exceed in their abstract, 
250 to 300 words is sufficient to address all items in the CONSORT for Abstracts 
guidelines.7,8 In addition, MEDLINE no longer truncates abstracts at a specific word 
count and instead allows up to 10,000 characters in an abstract,21 questioning whether 
journals should be imposing a specific word limit at all. 
The proportions of RCTs that met each criterion in 2010 were similar to a previous study, 
with many RCTs not meeting the CONSORT for Abstracts guidelines.9 Since that study 
found that more criteria were met after the CONSORT for Abstracts guidelines were 
published,9 it would be expected that this study would see continued increases in 
adherence. Other than the interventions and objectives criteria, the percentage of RCTs in 
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2016 that reported each criterion in the abstract increased from a previous study in 
anesthesiology journals.9 
Since the first thing readers see is the title, it is important to identify that the trial is 
randomized in the title. In Table 4-2, this CONSORT for Abstracts criterion was 
separated into three sections (reported in the title, reported in the abstract, or reported in 
the full-text manuscript) to show where authors were first describing that their trial was 
randomized. From 2010 to 2016, the percentage of RCTs with the word randomized in 
the title almost tripled, but almost a quarter of RCTs in 2016 still did not have the word 
randomized in the title. This is a very simple item that authors can easily achieve and 
editors can easily check for. 
As expected, most RCTs included had a parallel groups and superiority design. However, 
many RCTs did not state whether they were conducting a superiority study in the 
abstract. Usually, the only way to determine whether the study was a superiority trial was 
from the objectives statement at the end of the Introduction or from the sample size 
calculation. In 2016, 68% of RCTs did not describe the trial design in the abstract, and of 
those, 68% had the trial design described in the full-text. The percentage of RCTs 
reporting the trial design in the abstract increased but among RCTs that did not report the 
trial design in the abstract, the percentage of RCTs reporting the trial design in the full-
text decreased. A potential reason for this finding is that most trials conducted were 
superiority trials with parallel arms, with authors only specifying when they were using 
an alternative study design. With the increase in alternative study designs being used, 
authors should ensure that they specify the trial design in the abstract even when a 
parallel group, superiority trial is being conducted.  
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This lack of specificity in the abstract also applies to the objective criterion where many 
RCTs only stated that they compared one intervention to another intervention in the 
abstract, not to determine which one was better. A previous study in anesthesiology 
journals found that around 90% of RCTs met this criterion,9 but this is likely due to a less 
stringent standard for having a clear objective. Another example of a lack of specificity is 
the Methods outcome criterion, where the primary reason for RCTs not meeting this 
criterion was not identifying which outcome was the primary outcome. The percentage of 
RCTs that describe their primary outcome increased from 2010 to 2016, but more authors 
need to ensure that they specify a primary outcome.  
Many criteria (participants, interventions, randomization, blinding, numbers randomized, 
recruitment, and numbers analyzed) show similar trends in terms of reporting in the 
abstract compared to reporting in the full-text only, with a high percentage of RCTs 
reporting the information in the full-text only. The participants criterion in the 
CONSORT for Abstracts guidelines consists of two dimensions, the eligibility criteria for 
participants and the setting where the data were collected.7 In 2016, only 42% of RCTs 
met this criterion, mostly due to the setting not being reported in the abstract. However, 
almost all RCTs that did not meet the criterion in the abstract had sufficient information 
in the full-text. As a result, abstract-only readers would not necessarily be able to know 
which patient population the results applied to.  
For the interventions criterion, even though a majority of the RCTs described the 
interventions in the abstract, all RCTs that did not do so described the intervention in the 
full-text. Thus, for some RCTs (29% in 2010 and 40% in 2016), the abstract would be 
omitting important details even though the information was available in the full-text. The 
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randomization criterion shows a more extreme trend, where the way randomization was 
conducted was rarely described in the abstract, with less than 2% in both years, consistent 
with a previous study.9 However, 88% of the trials in 2016 described this information in 
the full-text, suggesting that authors were choosing not to report this information in the 
abstract, not that the information was unavailable. Most authors just reported that the 
RCT was randomized in the abstract and not how participants were allocated to each 
group. Most RCTs in general medical journals also failed to meet this criterion, with 
fewer than 8% of RCTs in the New England Journal of Medicine, Journal of the 
American Medical Association, and BMJ reporting the method of random sequence 
generation in the abstract.10 However, in the Lancet, 89% of RCTs reported the method 
of random sequence generation and 39% reported the method of allocation concealment 
in the abstract.10 
For the blinding criterion, a similar trend was seen, but with a smaller gap since we 
considered RCTs as meeting the criterion even if they only used the terms single or 
double blinding. Even when using this relaxed criterion, only about 37% of RCTs 
reported the blinding in the abstract. This may be due to RCTs that did not use blinding in 
the RCT rarely mentioning a lack of blinding in the abstract. The recruitment criterion 
also followed this trend since RCTs that did not terminate early rarely reported the trial 
status. The proportion reporting in the full-text was almost 100% since we considered 
RCTs to meet this criterion if the number recruited met or exceeded the target sample 
size. Either RCTs should always report the trial status or this item should only be relevant 
when a trial is terminated early. 
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For the numbers randomized and numbers analyzed criteria, the percentage of RCTs 
adhering to the CONSORT for Abstracts guidelines increased by about 5% from 2010 to 
2016. However, many RCTs did not have sufficient information in the abstract, often due 
to reporting a total sample size and not the number per group. The proportion of RCTs 
meeting the numbers analyzed criterion was lower than the numbers randomized criterion 
since many RCTs did not mention in the abstract if all patients were analyzed with no 
loss to follow-up. However, likely due to the increasingly widespread use of the 
CONSORT flow diagram,22,23 all RCTs that did not meet these two criteria in the abstract 
reported the information in the full-text.  
The percentage of RCTs that met the Results outcome criterion in the abstract increased 
from 6% in 2010 to 40% in 2016. While this is a large increase, more than half of the 
RCTs were still not adequately reporting this item. Most RCTs typically only reported a 
result for each group and a p-value, with few studies reporting an effect size and 
precision for that effect size. By comparison, in 2006, 62% of RCTs in major general 
medical journals reported the effect size and confidence interval in the abstract.24 Of the 
RCTs in 2016 that did not meet the criterion in the abstract, only 24% met the criterion in 
the full-text. Since most anesthesiology RCTs were incorrectly reporting their results, the 
CONSORT for Abstracts guidelines was not able to be followed because the general 
CONSORT guidelines were not being followed. The harms criterion has a similar trend, 
though only a minority of RCTs were not reporting the harms. The percentage of RCTs 
reporting the harms in the abstract increased from 49% in 2010 to 59% in 2016 while the 
percentage of RCTs reporting the harms in the full-text decreased from 68% to 64%. This 
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suggests that the lack of harms reporting in the abstract is partially due to harms not being 
assessed in the RCT.  
The conclusions criterion was the best reported, with over 90% of RCTs having a 
conclusion in the abstract. Corresponding with results from Chapter 3 suggesting an 
increase in trials being registered over time, the proportion of RCTs reporting trial 
registration in the abstract also increased. However, many RCTs still only reported the 
trial registration in the full-text and not the abstract. A distinct journal difference was 
observed in 2016, with almost no RCTs from Anaesthesia, Anesthesia & Analgesia, and 
Anesthesiology reporting the trial registration in the abstract even though 25%, 51%, and 
65% of these RCTs had the trial registration reported in the full-text, respectively. In 
contrast, British Journal of Anaesthesia, Canadian Journal of Anesthesia, European 
Journal of Anaesthesiology reported the trial registration in the abstract for 53%, 54%, 
and 35% of the RCTs, respectively. 
Just like in a previous study,9 the funding source was never reported in the abstract. 
However, the percentage of RCTs that reported the funding source in the full-text 
increased from 70% in 2010 to 95% in 2016. Despite CONSORT for Abstracts 
guidelines, the funding source is always reported in the full-text only and not the abstract. 
Perhaps the authors of the CONSORT for Abstracts guidelines should consider removing 
this criterion or making it only applicable for conference abstracts, similar to the contact 
details for the corresponding author. 
Potential limitations must be considered when interpreting the conclusions of this study. 
Since there are many factors contributing to whether an item is reported in the abstract, 
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such as space limitation, journal policy, author preference, and lack of available 
information, the exact reason for each RCT failing to meet a criterion is hard to determine 
even though there is an overall trend. Though two reviewers screened for eligible RCTs, 
each RCT had data extraction performed by one reviewer, potentially increasing the 
amount of error if the reviewers were inconsistent. To reduce the subjectivity of criteria 
and potential error, reviewers were trained prior to data extraction with the same 
guidelines and a second reviewer was consulted if any variable was unclear.  
Another limitation is that cross-over trials are more likely to meet certain criteria since 
the same group is used for both treatment and control. For example, in the trial design 
criterion, cross-over trials do not need to specify that it is a parallel group design or in the 
numbers randomized criterion, the total number of participants is the same as the 
participants per arm. Finally, the overall adherence and full-text-only scores considered 
each CONSORT for Abstracts criterion as equally important, preventing an assessment of 
how much distortion the failure to report would cause a typical reader. 
In conclusion, RCTs in the top six general anesthesiology journals have improved their 
adherence to the CONSORT for Abstracts guidelines from 2010 to 2016, but the level of 
adherence is still lacking. Even in 2016, around 75% of RCTs meet fewer than half of the 
16 criteria with no RCTs reporting all 16 items in the abstract. Other than the Results 
outcome criterion, a majority of the RCTs have the information present in the full-text, 
but not reported in the abstract. This suggests that per the CONSORT for Abstracts 
guidelines, the abstracts for many anesthesiology RCTs are an incomplete summary of 
the entire manuscript. An alternative explanation is that some items are unrealistic for 
real-world application, with more investigation needed to determine which items would 
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provide the most impactful information. More research needs to be conducted to 
determine what tools can be used to improve the abstract reporting for anesthesiology 
RCTs and whether the CONSORT for Abstracts statement is appropriate.  
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5.1 Introduction 
In evidence-based medicine, randomized clinical trials (RCTs) are considered to provide 
the highest quality of evidence with the least amount of bias,1 representing the gold 
standard for assessing therapeutic interventions.2 In every study, participants are needed 
to provide data. However, the ideal number of participants cannot be determined without 
appropriate calculations. A sample size calculation involves determining the minimum 
number of participants needed to detect a treatment effect that is clinically relevant.3 An 
inadequately small sample size may result in the inability to detect a precise effect, if 
present, while a needlessly large sample size may result in extra participants being 
exposed to the potential risks of the trial.4 While there are ethical debates over whether 
underpowered trials should be conducted, an a priori sample size calculation should still 
be conducted and reported to ensure methodological quality.5 
The Consolidated Standards of Reporting Trials (CONSORT) statement is a set of 
guidelines aimed at improving the quality of RCT reporting.6 Item seven in the most 
recent checklist focuses on sample size, with recommendations to explain how sample 
size was determined and, ideally, to possess a high probability of detecting a statistically 
significant, clinically relevant difference if one exists.6 The components needed for a 
sample size calculation are: the expected outcomes for each group (which implies the 
clinically relevant effect size), the type I (α) error level, the type II (β) error or power (1-
β) level, the standard deviation for continuous outcomes, and any allowances made for 
attrition or non-compliance, if appropriate.6,7 
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In six high impact factor general medical journals, 95% of two-arm, parallel group, 
superiority RCTs reported a sample size calculation but only 53% reported all parameters 
required for sample size calculation.8 For the RCTs that reported all parameters for 
sample size calculation, investigators replicated the sample size calculations and found 
that 18% of the replicated sample sizes were more than 10% lower than the reported 
sample size and 12% were more than 10% higher than the reported sample size.8 In ten 
high impact factor anesthesiology journals, similar results were found for RCTs 
published in 2013, with 8.3% not reporting a sample size calculation and 28.7% of 
sample size recalculations more than 10% different from the reported sample size.9 While 
the investigators found differences between the expected and actual values for each 
sample calculation parameter,9 only the medians and interquartile ranges of the 
differences were presented and not the number of RCTs with over 10% difference 
between the expected and actual values. 
The current study focused on anesthesiology RCTs, specifically two-arm, parallel group, 
superiority RCTs published in the top six general anesthesiology journals as determined 
by impact factor. The first objective of this study was to compare RCTs published in 
2010 and 2016 in terms of the proportion that performed an a priori sample size 
calculation and the proportion that reported the necessary elements to allow for 
replication. This would update the literature using the most recent RCTs and examine 
potential trends over time in sample size calculation reporting. The second objective was 
to compare the expected sample size calculation parameters with the actual values 
observed in the results. The third objective was to perform post-hoc power calculations 
for the primary and first two reported secondary outcomes of each RCT. While post-hoc 
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power does not help with interpreting the results of a study since, by definition, a 
nonsignificant difference will always have low post-hoc power,10 this exercise was not 
intended to interpret the results, but solely to examine the suitability of the sample size 
calculation.  
5.2 Methods 
An electronic database had been created for a previous project to collect all RCTs 
published in 2010 and 2016 from the top six general (non-pain-centric) anesthesiology 
journals as determined by impact factor: Anaesthesia, Anesthesia & Analgesia (A&A), 
Anesthesiology, British Journal of Anaesthesia (BJA), Canadian Journal of Anesthesia 
(CJA), and European Journal of Anaesthesiology (EJA).11 Detailed screening and data 
extraction have been described previously in Chapters 3 and 4, with the study protocol 
publicly available as well.12  
A RCT was defined as a prospective study that assessed randomly allocated health care 
interventions in human participants where authors had clearly reported that participants 
had been randomly allocated to study arms (i.e. the use of the words “random”, 
“randomized”, or “randomised”). The Table of Contents located on each journal’s 
website was independently searched by two reviewers for eligible RCTs. Any 
disagreements were discussed with a third reviewer with a decision made by consensus. 
Because only RCTs were included, all observational studies (e.g. case-control or cohort 
studies), learning curve studies, cadaver studies, cost-effectiveness studies, dose-finding 
or dose-response studies which were not designed to test a clinical intervention, 
diagnostic test accuracy studies, meta-analyses, editorials, narrative reviews, animal 
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studies, manikin studies, and re-analyses of previously published studies were excluded. 
RCTs published in the correspondence section, the letters to the editor section, or 
supplemental issues were also excluded. If a study reported more than one phase, data 
was only extracted from the phase with the highest number of participants. RCTs from 
this database were automatically screened for inclusion in the current study, with RCTs 
only eligible if there were two study arms and a parallel group, superiority design.  
General characteristics such as journal, year, multicentricity, trial registration status, and 
sample size had been previously extracted for each RCT and those values were used to 
calculated summary measures for RCTs included in this study. RCTs were deemed 
adequately registered if the trial was registered in a publicly available trials registry prior 
to the first participant being enrolled with a clearly defined primary outcome. To 
determine trial registration status, the assigned reviewer searched the full-text for trial 
registration information. If no information was found, the reviewer searched 
www.clinicaltrials.gov, the International Standard Randomized Controlled Trial Number 
Register (ISRCTN), and the World Health Organization (WHO) Clinical Trials Search 
Portal. If no information was found during the registry search, two attempts separated by 
one week were made to contact the corresponding author via email for registration 
information. If none of these steps produced registration information, the study was 
considered not registered. Trials registered at the European Union Clinical Trials Register 
(EUCTR) were considered to be not registered to ensure consistency since the registry 
was only made publicly available in 2011.13 Sample size was defined as the number 
randomized in the trial. The statistical software used for each RCT was also extracted, 
with the primary statistical package recorded if more than one was reported. 
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Data extraction for the current study was performed by one of four reviewers for data 
extraction. A second reviewer provided input if variables were unclear and a decision was 
made by consensus. During data extraction, the full-text of each included RCT was 
searched for the presence of a sample size calculation. Analyses were only performed for 
RCTs that had a sample size calculation that was amenable to replication, defined as 
using a clearly identified outcome that was continuous or binary in a standard sample size 
calculation procedure. For RCTs with sample size calculations amenable to replication, 
the assumptions made by the investigators were recorded such as the expected outcome 
for the treatment group, the expected outcome for the control group, the type I (α) error 
level, the type II (β) error level, and whether any allowances were made for attrition or 
non-compliance. The standard deviation was also recorded for RCTs that used a 
continuous outcome in their sample size calculation. The actual values for the treatment 
group outcome, control group outcome, and standard deviation were also recorded to 
determine if the difference between actual and expected values was within 10% of the 
expected value. The justifications for these assumptions were recorded using a 
categorical outcome with options for published trial, meta-analysis, pilot study, 
observational data, unspecified, and other.  
For studies that provided all assumptions needed to replicate the sample size (i.e. 
expected outcome for treatment group, expected outcome for control group, type I (α) 
error level, Type II (β) error level, and standard deviation for continuous outcomes), the 
sample size was replicated using both the user-written add-on command, ssi,14 and the 
power command in Stata. When provided in the sample size calculation, the allowances 
made for attrition or non-compliance were included in the recalculation to ensure 
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accuracy. The two replicated sample sizes were compared with the reported target sample 
size, with the sample sizes deemed to be equivalent for the purposes of this study if either 
replicated sample size had a difference of 10% or less on either side of the target sample 
size. When the difference (positive or negative) was greater than 10%, a discrepancy was 
noted and values checked again to ensure accuracy. For one-sided sample size 
calculations, the type I (α) error level was doubled and the same procedures followed. 
During data extraction, some trials with binary outcomes were found to not specify 
whether relative or absolute differences were expected. In those cases, both alternatives 
were tried with the replicated sample size closest to the reported target sample size used. 
The outcome type, actual outcome value for the treatment group, actual outcome value 
for the control group, standard deviation for the treatment group, standard deviation for 
the control group, and the specified type I (α) error level were extracted for the primary 
and first two unique secondary outcomes (secondary outcomes were considered to be not 
unique if they assessed the same outcome but at different time points). If there was more 
than one primary outcome, the one used in the sample size calculation was selected. For 
sample size calculations using a one-sided test, the type I (α) error level was doubled for 
the primary outcome only. Only binary and continuous outcomes (reporting a mean and 
standard deviation) were included to ensure post-hoc power could be calculated. If a 
secondary outcome was not binary or continuous, the next secondary outcome was used 
instead. Using the reported sample size and assuming equal allocation to groups, the user-
written add-on command, ssi, in Stata14 was used to calculate post-hoc power. The 
sample size was defined as the number of participants randomized. The mean for the 
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post-hoc powers of each RCT’s two secondary outcomes was recorded, with an overall 
mean and standard deviation calculated for all RCTs.  
The post-hoc powers for each RCT were categorized as meeting the minimum thresholds 
(70% and 80%) or not. An a priori decision was made to use an 80% threshold value 
since most RCTs target a power of 80%, and a 70% threshold value to assess the number 
of RCTs close to meeting the target threshold. Due to the relationship between post-hoc 
power and statistical significance, the post-hoc power results were then stratified by 
whether the RCT was statistically significant. A RCT was defined as statistically 
significant if the manuscript indicated statistical significance for the primary outcome 
used in the sample size calculation. 
Descriptive statistics were used to present the raw numbers and percentages for all 
measured outcomes. All analyses were conducted using Stata 13 statistical software 
(StataCorp LLC, College Park, Texas). 
5.3 Results 
Of the 395 RCTs identified through duplicate hand-searching of the Table of Contents for 
the top six general anesthesiology journals (Anaesthesia, A&A, Anesthesiology, BJA, 
CJA, and EJA), 255 RCTs met the inclusion criteria of being parallel, superiority RCTs 
with two study arms (Figure 5-1). There were 143 RCTs from 2010 and 112 RCTs from 
2016, with decreases in the number of RCTs from each journal other than Anesthesiology 
and CJA (Table 5-1). Most RCTs occurred at a single centre. Though SPSS was the most 
commonly used statistical software, the number of RCTs using SPSS decreased from 
2010 to 2016; this coincided with increases in the use of Stata, SAS, and R. The 
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percentage of adequately registered RCTs increased almost seven-fold from 2010 to 2016 
even though more than half of RCTs in 2016 were still inadequately registered (Table 5-
1). 
 
Figure 5-1: Flowchart for inclusion of trials 
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Table 5-1:  Characteristics of included RCTs 
Data presented are the number of trials (%) unless otherwise stated. Percentages may not add up to 100% 
due to rounding. IQR means interquartile range. 
1 Multi-centre is defined as participants recruited from more than one institution or clinic  
2 Adequate registration is defined as the trial being registered before the first participant was enrolled with a 
primary outcome clearly defined in the registry. 
 2010 
(n=143) 
2016 
(n=112) 
Journal   
Anaesthesia 28 (20%) 22 (20%) 
Anesthesia & Analgesia 37 (26%) 21 (19%) 
Anesthesiology 11 (8%) 13 (12%) 
British Journal of Anaesthesia 24 (17%) 22 (20%) 
Canadian Journal of Anesthesia 12 (8%) 17 (15%) 
European Journal of Anaesthesiology 31 (22%) 17 (15%) 
Multicentricity1   
Single-centre  137 (96%) 97 (87%) 
Multi-centre 6 (4%) 15 (13%) 
Statistical Software   
 SPSS 68 (48%) 46 (41%) 
 Stata 10 (7%) 14 (13%) 
 SAS 8 (6%) 18 (16%) 
 R 1 (1%) 8 (7%) 
 JMP 2 (1%) 3 (3%) 
 Other 27 (19%) 14 (13%) 
 GraphPad (Prism/InStat) 9 (6%) 7 (6%) 
 SigmaPlot/SigmaStat 2 (1%) 3 (3%) 
 Statistica 2 (1%) 1 (1%) 
 StatView 4 (3%) 0 (0%) 
 Other 10 (7%) 3 (3%) 
 Not Mentioned 27 (19%) 9 (8%) 
Trial Registration2   
Adequately Registered 8 (6%) 46 (41%) 
Inadequately Registered 135 (94%) 66 (59%) 
Median Sample Size (IQR) 63 (41–101) 80 (52–135.5) 
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Only 110 RCTs in 2010 and 88 RCTs in 2016 had a sample size calculation amenable to 
replication, with a standard sample size calculation that used a clearly identified binary or 
continuous outcome (Table 5-2). The percentage of RCTs reporting all assumptions 
(expected outcome for treatment group, expected outcome for control group, type I error 
level, type II error level, and standard deviation for continuous outcomes) increased from 
51% in 2010 to 84% in 2016. However, the difference between the actual and expected 
values for most RCTs was usually greater than 10% of the expected value, with 
negligible improvement from 2010 to 2016. Most RCTs based their sample size 
calculations on published trials, with the percentage continuing to increase in 2016 (Table 
5-2).  
Table 5-2:  Reporting and accuracy of sample size assumptions in RCTs 
Data presented are the number of trials with the specific criterion reported / number of eligible trials (%) 
unless otherwise specified. Percentages may not sum to 100% due to rounding. 
1 Number of trials where the actual value is within 10% of the assumption / number of trials with both the 
specific assumption and the actual value is reported (%). 
2 For trials using a continuous outcome in their sample size calculation 
3 Subgroups are not mutually exclusive so percentages will sum to over 100% 
 2010 2016 
Sample size calculation amenable to replication 110/143 (77%) 88/112 (79%) 
 No sample size calculation 16/33 (48%) 4/24 (17%) 
 Not amenable to replication 17/33 (52%) 20/24 (83%) 
Assumptions   
Estimated outcome for treatment group 70/110 (64%) 76/88 (86%) 
Actual values within 10%1 14/62 (23%) 17/68 (25%) 
Estimated outcome for control group 70/110 (64%) 76/88 (86%) 
Actual values within 10%1 26/62 (42%) 24/68 (35%) 
Type I (α) error level 108/110 (98%) 88/88 (100%) 
Type II (β) error or power level 108/110 (98%) 88/88 (100%) 
Standard deviation2 36/74 (49%) 50/54 (93%) 
Actual values within 10%1,2 3/21 (14%) 4/21 (19%) 
Allowances made for attrition or non-compliance 30/110 (27%) 47/88 (53%) 
All assumptions reported 56/110 (51%) 74/88 (84%) 
Justification for assumptions3   
Published trial (RCT) 36/110 (33%) 45/88 (51%) 
Meta-analysis 3/110 (3%) 1/88 (1%) 
Pilot study 30/110 (27%) 21/88 (24%) 
Observational data 14/110 (13%) 14/88 (16%) 
Unspecified 18/110 (16%) 8/88 (9%) 
Other 18/110 (16%) 7/88 (8%) 
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When replicating the initial sample size calculation for RCTs with all assumptions 
reported, 70% of RCTs estimated a sample size similar to the recalculated sample size, 
after including a 10% margin of error (Table 5-3). The average post-hoc power for 
primary and secondary outcomes decreased from 2010 to 2016, with large standard 
deviations. When categorizing the post-hoc power as meeting thresholds of 70% or 80%, 
most statistically significant RCTs had a primary post-hoc power greater than or equal to 
the threshold; as expected, RCTs that were not statistically significant had a low post-hoc 
power. For statistically significant RCTs, the percentage of RCTS having a post-hoc 
secondary outcome power ≥70% or ≥80% was about half of the percentage of RCTs 
having a post-hoc primary outcome power ≥70% (Table 5-3). Figure 5-2 shows the 
primary post-hoc power distributions stratified by whether the RCT is statistically 
significant, with RCTs that are not statistically significant having a lower post-hoc 
primary outcome power than RCTs that are statistically significant. Though the 
interquartile ranges are large, the median post-hoc power for the primary outcome 
appears to decrease from 2010 to 2016 irrespective of statistical significance (Figure 5-2).   
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Table 5-3: Replication of sample size calculations for included RCTs 
Data presented are the number of trials / number of eligible trials (%) unless otherwise stated. 
1 Number of trials where the replicated initial sample size is within 10% of the reported target sample size / 
number of trials with all sample size assumptions reported (%)  
2 Data presented as mean (standard deviation) post-hoc power; N = number of eligible trials 
3 Statistical significance as defined by what was reported in the manuscript for the primary outcome 
 2010 2016 
Replication of initial sample size calculation1 39/56 (70%) 52/74 (70%) 
Average post-hoc power   
Primary outcome2 0.65 (0.36) 
N=69 
0.49 (0.38) 
N=57 
Average of first two reported secondary outcomes2 0.50 (0.31) 
N=101 
0.40 (0.31) 
N=80 
Number of statistically significant RCTs3 76/110 (69%) 50/88 (57%) 
Primary outcome ≥ 80% post-hoc power 33/43 (77%) 19/29 (66%) 
Primary outcome ≥ 70% post-hoc power 37/43 (86%) 20/29 (69%) 
Secondary outcomes ≥ 80% post-hoc power 19/70 (27%) 11/43 (26%) 
Secondary outcomes ≥ 70% post-hoc power 25/70 (36%) 16/43 (37%) 
Number of non-statistically significant RCTs3 34/110 (31%) 38/88 (43%) 
Primary outcome ≥ 80% post-hoc power 1/25 (4%) 0/28 (0%) 
Primary outcome ≥ 70% post-hoc power 1/25 (4%) 0/28 (0%) 
Secondary outcome ≥ 80% post-hoc power 1/31 (3%) 1/37 (3%) 
Secondary outcome ≥ 70% post-hoc power 5/31 (16%) 1/37 (3%) 
 
Figure 5-2: Distribution of primary post-hoc power stratified by statistical 
significance of the trial 
White line represents median; box represents 25th and 75th percentiles; each whisker represents 1.5 times 
interquartile range; dots represent outside values 
105 
 
For RCTs where the primary outcome used in the sample size calculation was binary (and 
when expected and actual values were reported for both the treatment and control 
groups), the majority of RCTs expected a larger effect size than the actual effect size 
observed (Table 5-4). From 2010 to 2016, there was an increase in the number and 
percentage of RCTs overestimating their effect sizes, but the mean absolute difference 
between the actual and expected effect sizes decreased (Table 5-4).  
Table 5-4: Comparison of estimated and reported effect sizes for binary outcomes 
Only trials where the primary outcome used in the sample size calculation was binary with estimated and 
actual values reported for both the treatment and control groups were included.  
Data presented are the number of trials (%) unless otherwise stated.  
1 Data presented as mean (standard deviation) absolute difference between the actual effect size and the 
estimated effect size (only trials that had the effect sizes overestimated were included) 
 2010 
(n=27) 
2016 
(n=30) 
Actual effect size < Estimated effect size 16 (59%) 23 (77%) 
Actual effect size ≥ Estimated effect size 11 (41%) 7 (23%) 
 Difference between actual and estimated1 8.85% (6.75%) 6.31% (6.48%) 
 
5.4 Discussion 
In the top six general anesthesiology journals, the percentage of two-arm parallel group, 
superiority RCTs with a sample size calculation increased from 89% in 2010 to 96% in 
2016. This is consistent with a previous study that found that 92% of anesthesiology 
RCTs in 2013 reported a sample size calculation.9 While this is encouraging, these 
sample size calculations may have been based on assumptions different from reality. 
Consistent with previous studies in top general medical journals and anesthesiology 
journals,8,9 about 30% of the initial size calculation replications were more than 10% 
different than the value estimated by the authors, suggesting that either researchers were 
calculating their sample sizes incorrectly or using non-standard sample size calculation 
formulas without specifying as such.  
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The assumptions needed for conducting sample size calculation were well reported, with 
increases seen in all sample size calculation parameters when comparing RCTs in 2016 to 
RCTs in 2010. The percentages in 2016 were also higher than a similar study in 2013,9 
suggesting an increase in sample size calculation reporting quality over time. Though 
Type I and Type II error levels were reported for all RCTs, the expected values for the 
treatment and control group were still below 90% in 2016, suggesting that the reason 
over 10% of RCTs were not explaining how the sample size was calculated was that the 
expected outcomes for the treatment and control group were not specified.  
More concerningly, the postulated effect estimates themselves were often different from 
what was observed. Most RCTs that reported both expected and reported values had 
discrepancies larger than 10%. Of the RCTs from 2016 with a continuous outcome used 
in the sample size calculation, only 19% found a pooled standard deviation that was 
within 10% of the expected pooled standard deviation. Large differences between 
estimates and actual sample size calculation parameters were also found in general 
medical journals.8 Around 80% of RCTs in general medical journals underestimated the 
sample size, with the actual standard deviation greater than the expected standard 
deviation.15 This may be due to different techniques being available to estimate the 
standard deviation using previously published literature or pilot studies, with some 
methods such as using the standard deviation from a small pilot study having a 50% 
chance of underestimating the standard deviation and resulting in an underpowered 
study.16 Investigators should be cautious when estimating sample size calculation 
parameters as the benefits of performing a sample size calculation are diminished if the 
estimates are inaccurate. However, the difficulty with estimating assumptions must also 
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be recognized; if the sample size calculation parameters are known with certainty, there 
may not be a need for a trial to be conducted. Since estimates are usually conducted in 
one of two ways, by using the treatment effect that is considered clinically meaningful or 
by using the treatment effect that is expected,17 the inaccuracy of estimates may be due to 
the intervention being ineffective or the potential effect being poorly estimated. For 
RCTs where the clinically important difference is used as the anticipated effect size in the 
sample size calculation, discrepancies would not imply any incorrect estimation by 
investigators. Due to the potential for meta-analyses to aggregate the results of RCTs, 
under-powered trials may still contribute valuable evidence if there is high 
methodological rigour, clear reporting, and a lack of publication bias.5 
With the sample size calculation assumptions different from what is observed, it would 
be helpful to also assess the power of the RCTs being conducted. While the importance 
of ensuring studies are adequately powered using a priori sample size calculations is 
widely accepted, calculating post-hoc power is inappropriate for interpreting the results 
of a study.10,18 However, this study performed post-hoc power to examine the effects of 
inaccurately estimating sample size calculation assumptions. Another study performed 
similar calculations for anesthesiology RCTs that had a negative primary outcome, 
finding a mean post-hoc power (95% confidence interval (CI)) of 0.20 (95% CI: 0.13 to 
0.27).9 Most RCTs use a 0.80 power level in their sample size calculation, but in 2016, 
the average post-hoc power using the actual values for the parameters used in the sample 
size calculation was only 0.49, with only 66% of statistically significant RCTs having a 
post-hoc primary outcome power of at least 80%. If the sample size calculation 
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assumptions are inaccurately estimated such that RCTs are inadequately powered, the 
value in performing sample size calculations is diminished. 
Since there is a direct relationship between p-values and post-hoc power, outcomes that 
are not statistically significant correspond to low post-hoc power.19 The distribution of 
the post-hoc power for primary outcomes, as shown in Figure 5-1, is consistent with this 
concept. On the other hand, the post-hoc power of secondary outcomes is unlikely to 
correspond to the statistical significance of a RCT’s primary outcome. A common 
concern when a trial has multiple secondary outcomes is an increase in the Type I error 
due to multiple testing.20 These secondary outcomes are often considered exploratory or 
hypothesis-generating, with most a priori sample size calculations only planning for 
adequate power for the primary outcome. By calculating the average post-hoc power for 
secondary outcomes, the results provide further support that secondary outcomes should 
be interpreted cautiously due to their low power. Interestingly, almost all RCTs that were 
not statistically significant had mean secondary outcome post-hoc powers below 70% as 
well. One potential explanation is that if a RCT is inadequately powered for the primary 
outcome, the secondary outcomes will likely be even more underpowered. 
Most sample size calculation parameters are poorly estimated and result in inadequately 
powered RCTs. Two potential solutions include improving estimates or using alternative 
methods to determine the sample size. Termed “sample size samba” or “delta inflation,” 
investigators commonly start with the number of available (or fundable) participants and 
adjust their estimates of the sample size calculation assumptions to justify their sample 
size.5,21 Increasing the expected effect size will increase the power,22 allowing for a 
smaller sample size to be calculated. For included RCTs with a binary outcome, the 
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majority find a smaller effect size than what was expected, showing one parameter that 
may be manipulated to produce a feasible sample size. If estimates are being manipulated 
in this way, it should be no surprise when the actual values are different from what is 
expected. Among the flaws of the traditional sample size calculation is the difficulty in 
accurately estimating all parameters and the design-use mismatch resulting from using a 
p-value cut-off to design a study that should not be interpreted based on a single p-
value.23 While performing sample size calculations can provide valuable information, less 
importance should be placed on these calculations due to the inherent subjectivity of the 
estimates.5 In the reporting of RCTs, confidence intervals may provide a better measure 
of uncertainty and better help readers understand the strength of the evidence.24 Some 
other alternatives to sample size calculations include using hybrid approaches, value of 
information methods, pragmatic methods based on cost or feasibility, sensitivity analyses, 
or using the same sample size as previous analogous studies.23,25,26  
The results of this study must be interpreted considering its limitations. Since this study 
only included two-arm, parallel group, superiority RCTs published in the top 
anesthesiology journals as determined by impact factor, the generalizability of the 
findings may be limited. While this study focused on the most commonly used trial 
design, different sample size calculations are used for different trial designs. Since only 
information from the published manuscript was used, definitive conclusions about sample 
size calculations being performed a priori cannot be made. Previous research has 
identified discrepancies in sample size calculations between published manuscripts and 
their original protocols27 so there is a chance of authors creating a sample size calculation 
based on the number of participants recruited. Another limitation was that analyses could 
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only be performed for RCTs that reported the relevant values. For example, RCTs that 
did not report all necessary sample size calculation assumptions could not be replicated to 
check for accuracy. For continuous outcomes, only those with a mean and standard 
deviation were used to compute post-hoc power, potentially making the results not 
applicable to RCTs with non-normal data reporting median and interquartile ranges. 
While two reviewers were used to screen for eligible RCTs, data extraction for each RCT 
was only performed by a single reviewer. To reduce potential inconsistency, all reviewers 
were trained using the same guidelines, with data quality checks throughout the process. 
In conclusion, almost all RCTs published in the top six general anesthesiology journals 
reported a sample size calculation. In 2016, most two-arm, parallel group, superiority 
RCTs included enough information in the methods section to allow for replication of the 
sample size calculation. While this represented a large increase from 2010, the outcome 
values and variability used in the sample size calculation were often different from what 
was observed, with most actual values having a difference from the expected value 
greater than 10%. The majority of RCTs using binary outcomes had a smaller reported 
effect size than was expected in the sample size calculation. More research needs to be 
conducted into how sample size calculation parameter estimates can be improved or 
whether alternative methods should be used to determine a trial’s ideal sample size. 
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6.1 Introduction 
Randomized clinical trials (RCTs) are prospective cohort studies where interventions are 
randomly allocated to participants.1 The methodological rigour of RCTs reduces the 
amount of bias inherent in clinical investigations, and this reduction in bias results in 
RCTs occupying the top of the evidence hierarchy for therapeutic interventions.2 
However, other factors may potentially negatively affect RCT quality, diminishing the 
credibility of some RCTs. One of these factors is the RCT’s funding source. 
The past few decades have seen a large increase in the number of industry-sponsored 
trials,3 with industry funding surpassing government or public funding in 2001.4 
Systematic reviews have often concluded that industry-sponsored studies are more likely 
to reach conclusions favourable to the sponsor.5–7 Reasons suggested for these findings 
include methodological quality, trial designs, publication biases, and interpretations of 
results.5,6,8 However, there is still no clear explanation for the association between 
industry funding and positive results.9  
Another aspect of funding source not studied is its effect, if any, in the anesthesiology 
literature. In the United States, anesthesiology continues to be underrepresented in 
National Institutes of Health (NIH) funding, with only 40% of current academic 
anesthesiology departments having at least one NIH grant credited to a faculty member or 
trainee and only 1% of the NIH budget going to anesthesiology departments, despite 
anesthesiologists representing 6% of the medical workforce.10 In Canada, the Canadian 
Institutes of Health Research (CIHR), the main source of government funding for 
medical research, has reduced funding by 7.5% adjusted for inflation from 2007 to 
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2013.11 With low government funding, other support sources such as industry funding 
may be employed at a more frequent rate compared to other specialties. Though more 
than half of original research in anesthesiology are clinical trials,12 results from Chapter 3 
show that the absolute number of anesthesiology RCTs have decreased over time.  
The effect of funding source on RCT quality has not yet been studied in the 
anesthesiology literature so we sought to elucidate the role of funding source, if any, in 
the anesthesiology literature. Our first objective was to determine what types of financial 
support fund RCTs in anesthesiology and whether there have been differences in funding 
source over time. Our second objective addressed whether the source of funding would 
bias the design and reporting quality of RCTs (as discussed in previous chapters). Trial 
registration, outcome switching, adherence to CONSORT for Abstracts, sample size 
calculations, and post-hoc power were used as outcomes to provide a new perspective for 
the potential distorting effect of funding on trial reporting. To align our study with the 
previous literature,5–7 our hypothesis was that most RCTs in the top six general 
anesthesiology journals would not be funded by industry, but those that were may 
potentially have had their quality negatively affected.  
6.2 Methods 
To facilitate previous projects, an electronic database was set up including all RCTs 
published in 2007, 2010, 2013, 2015, and 2016 for the top six general (non-pain-centric) 
anesthesia journals as determined by impact factor: Anaesthesia, Anesthesia & Analgesia 
(A&A), Anesthesiology, British Journal of Anaesthesia (BJA), Canadian Journal of 
Anesthesia (CJA), and European Journal of Anaesthesiology (EJA).13 Other than funding 
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source, all data had previously been collected (see chapters 3, 4, and 5). The following 
five paragraphs outline the screening and data extraction methods that were conducted in 
previous chapters, with the study protocol also being publicly available.14  
Two reviewers independently searched the Table of Contents on each journal’s website to 
screen for eligible RCTs, with disagreements resolved by consensus with a third 
reviewer. RCTs were eligible if they were prospective studies that assessed randomly 
allocated health care interventions in human participants and identified by authors clearly 
reporting that patients had been randomly allocated to study arms (i.e. the use of the 
words “random”, “randomized”, or “randomised”). Studies were not included if they 
were observational studies (e.g. case-control, or cohort studies), learning curve studies, 
cadaver studies, cost-effectiveness studies, dose-finding or dose-response studies which 
were not designed to test a clinical intervention, diagnostic test accuracy studies, meta-
analyses, editorials, narrative reviews, animal studies,  manikin studies, simulation 
studies, duplicate reports, re-analyses of previously published RCTs, studies published in 
the correspondence section, letters to the editor, or studies part of supplemental issues.  
RCTs identified as eligible were prospectively included in an electronic database for data 
extraction. Data extraction was conducted by one reviewer with any uncertainty 
discussed with a second reviewer and a decision made by consensus. After extracting 
general characteristic information such as year and journal, the trial registration status 
was assessed. An RCT was only included if the RCT had been registered in a publicly 
available trials registry prior to the first patient being enrolled and had a clearly defined 
primary outcome. If registration information was not found in the manuscript, trial 
registries (www.clinicaltrials.gov, the International Standard Randomized Controlled 
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Trial Number Register, and the WHO Clinical Trials Search Portal) were searched. If no 
results were found after the search, the corresponding author was contacted using two 
standardized emails with one week in between. If the date of trial registration occurred 
after the date of first patient enrollment, the RCT was considered to be inadequately 
registered. If the first patient enrollment date was not provided, the study start date was 
used instead. A RCT was considered to have a clearly defined primary outcome if the 
primary outcome was clearly and unambiguously defined with a specific time frame in 
both the trials registry and the manuscript.   
The presence of outcome discrepancies was assessed for all included RCTs in 2007, 
2010, 2013, and 2015. A RCT was considered to have a primary outcome discrepancy if 
a registered primary outcome was not reported as a primary outcome, a reported primary 
outcome was not registered as a primary outcome, or the timing of a reported primary 
outcome differed from a registered primary outcome. A RCT was considered to have a 
secondary outcome discrepancy if a registered secondary outcome was not reported as a 
secondary outcome, a reported secondary outcome was not registered as a secondary 
outcome, or the timing of a reported secondary outcome differed from a registered 
secondary outcome. Any outcome discrepancy was defined by a RCT having either a 
primary or secondary outcome discrepancy. 
In Chapters 4 and 5, data extraction was conducted by one of four assigned reviewers. 
Only RCTs published in 2010 and 2016 were included. Uncertain variables were 
discussed with a third reviewer, with a decision made by consensus. The general 
characteristics for each RCT were extracted such as journal, year, multicentricity, study 
design, sample size, and trial registration status. Sample size was defined as the number 
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randomized and adequately registered was defined as a RCT registered in a publicly 
available trials registry prior to the first patient being enrolled with a clearly defined 
primary outcome. Reviewers assessed the abstract and full-text for each item in the 
CONSORT for Abstracts statement, with each item recorded as reported in the abstract, 
not reported in abstract but reported in manuscript, or not reported in abstract or 
manuscript. While there are 16 items in the CONSORT for Abstracts statement, each 
individual item was not analyzed separately for the current study. The outcomes assessed 
as being reported in the abstract were title, trial design, methods (at least five of six 
criteria met), results/conclusions (at least five of six criteria met), and all checklist items 
(number of criteria met). 
For sample size outcomes, only two-arm, parallel group, superiority RCTs were included 
for analysis. In Chapter 5, each RCT was examined for the presence of a sample size 
calculation. If there was a sample size calculation, the text would be examined to 
determine if all assumptions necessary for replication were included such as expected 
outcome for treatment group, expected outcome for control group, type I (α) error level, 
type II (β) error/power level, and standard deviation for continuous outcomes. The RCT 
was also classified as statistically significant if the manuscript indicated statistical 
significance for the primary outcome used in the sample size calculation. For RCTs that 
included all assumptions necessary for replication, the sample size calculation was 
repeated using the user-written add-on command, ssi,15 and the power command in Stata. 
RCTs were considered to be accurately replicated if either replicated sample size had a 
difference from the reported target sample size that was 10% or less. For the primary and 
first two unique secondary outcomes (i.e. not the same time point) reported, the outcome 
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type, actual outcome value for the treatment group, the actual outcome value for the 
control group, the standard deviation for the treatment group, the standard deviation for 
the control group, and the specified type I (α) error level were extracted. Only binary and 
continuous outcomes were used. Along with the sample size extracted previously, these 
values were used with the user-written add-on command, ssi, in Stata15 to calculate the 
post-hoc power for each outcome assuming equal allocation of participants. For each 
RCT, the mean of the two secondary outcomes was taken to produce a single value for 
the secondary outcome post-hoc power. 
To assess the potential impact of industry funding, RCTs published in 2016 were used for 
all outcomes, except for the outcome discrepancy outcomes which used RCTs published 
in 2015 due to data limitations. During data extraction for the current study, the funding 
source for each RCT was recorded using a categorical outcome with options: no funding; 
only industry; university, hospital, or government; private non-profit; multiple sources of 
funding (including industry involvement); multiple sources of funding (no industry 
involvement); other; or not reported. Using this variable, two groupings were created for 
analysis. Grouping One compared industry-only funding to non-industry-only funding, 
with non-industry-only funding comprising of RCTs with either no funding; university, 
hospital or government; private non-profit; other; multiple sources of funding (including 
industry); or multiple sources of funding (no industry). Grouping Two compared any 
industry funding to no industry funding, with any industry funding comprising of RCTs 
with either only industry or multiple sources of funding (including industry) and no 
industry funding comprising of RCTs with either no funding; university, hospital or 
government; private non-profit; other; or multiple sources of funding (no industry). 
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Descriptive statistics were used to present the raw numbers and percentages for all 
measured outcomes. A chi-squared test for linear trend with the year published as a 
continuous outcome was used to assess the change in funding between the measured 
years: 2007, 2010, 2013, 2015, 2016. To determine whether the type of funding had an 
effect on trial reporting, simple logistic regression was used for binary outcomes and 
simple linear regression was used for continuous outcomes. All outcomes were binary 
(i.e., the RCT either met the criteria or not) except for the overall CONSORT for 
Abstracts checklist item score, primary outcome post-hoc power, and secondary outcome 
post-hoc power. Stata 13 statistical software (College Park, Texas) was used to conduct 
all analyses. The analysis was conducted twice for each outcome, once with Grouping 
One as the explanatory variable where industry-only funding was compared to non-
industry-only funding, and once with Grouping Two as the explanatory variable where 
any industry funding was compared to no industry funding. RCTs where the funding 
source was not reported were excluded from these analyses.  
6.3 Results 
A total of 1,036 RCTs were included, with 316 RCTs from 2007, 219 RCTs from 2010, 
170 RCTs from 2013, 155 RCTs from 2015, and 176 RCTs from 2016 (Table 6-1). A 
decreasing number of RCTs were identified with each successive year, except in 2016, 
which had more RCTs than 2013 and 2015. The number and percentage of RCTs where 
the funding source was not reported consistently decreased with each successive year 
examined from 2007 to 2016. In every year examined, the university, hospital, or 
government category was the most prevalent funding source for RCTs. Industry funding 
represented a minority of anesthesiology RCTs, when measured using Grouping One or 
122 
 
Grouping Two (Table 6-1). Figure 6-1 illustrates the funding source for each of the 
included journals in 2010 and 2016. Notably, in 2016, Anesthesiology had the highest 
percentage of RCTs funded by industry and CJA had no RCTs funded by industry (Figure 
6-1). 
The results of simple regression models assessing the impact of industry funding on 
included RCTs from 2015/2016 only were inconclusive (Table 6-2). For all outcomes 
where linear and logistic regression was able to be performed, only the trial design 
element of the CONSORT for Abstracts statement for Grouping Two was statistically 
significant. All RCTs in 2015 funded fully or in part by industry had at least one outcome 
discrepancy and no RCTs in 2016 funded fully or in part by industry reported all sample 
size assumptions. For post-hoc power outcomes, regression models were also performed 
stratified by whether the RCT was statistically significant, though some could not be 
performed since the primary outcome post-hoc power was always low for RCTs that 
were not statistically significant (Table 6-2).  
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Table 6-1: Funding source of RCTs by year 
Data presented are the number of trials (%). Percentages may not add up to 100% due to rounding. 
1 Non-industry-only funding is the sum of trials with: no funding; university, hospital or government; private non-profit; other; or multiple sources of funding 
2 Grouping 2 consists of trials from 2010, 2015, and 2016 where the funding source is reported. Any industry refers to the funding source being only industry or 
having multiple sources of funding with at least one being industry; no industry refers to the funding source being non-industry or having multiple sources of 
funding with none being industry.  
Statistical Significance: Denotes the p-value for the chi-squared test for linear trend  
 
Funding Source 
2007 
(n=316) 
2010 
(n=219) 
2013 
(n=170) 
2015 
(n=155) 
2016 
(n=176) 
Statistical 
Significance 
Not reported 156 (49%) 66 (30%) 15 (9%) 12 (8%) 8 (5%) p<0.0001 
Grouping One       
No funding 12 (4%) 7 (3%) 37 (22%) 37 (24%) 42 (24%) p<0.0001 
Only industry 29 (9%) 22 (10%) 13 (8%) 9 (6%) 13 (7%) p=0.0001 
University, hospital, or government 82 (26%) 103 (47%) 82 (48%) 76 (49%) 76 (43%) p=0.08 
Private non-profit 8 (3%) 6 (3%) 5 (3%) 8 (5%) 9 (5%) p=0.76 
Other 0 (0%) 1 (0%) 0 (0%) 0 (0%) 0 (0%) p=0.51 
Multiple sources of funding 29 (9%) 14 (6%) 18 (11%) 13 (8%) 28 (16%) p=0.45 
Non-industry only funding1 131 (41%) 131 (60%) 142 (84%) 134 (86%) 155 (88%) p=0.0001 
Grouping Two2 N/A (n=153) N/A (n=143) (n=168)  
Any industry N/A 34 (22%) N/A 19 (13%) 30 (18%) N/A 
No industry N/A 119 (78%) N/A 124 (87%) 138 (82%) N/A 
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Figure 6-1: Funding source of RCTs by journal for 2010 and 2016 
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Table 6-2: Results of simple regression models for the impact of industry funding in included RCTs from 2015/2016 only 
The Trial Registration section uses 2015 data while the CONSORT and Sample Size sections use 2016 data. Data presented are the odds ratio (95% CI; p-value) 
unless otherwise stated. Grouping One compares industry-only funding to non-industry-only funding (reference group). Grouping Two compares any industry 
funding to no industry funding (reference group). 
n = number of trials included in the regression model 
1 Outcome was met if at least five of six CONSORT for Abstracts criteria were reported in the abstract 
2 Data presented as average difference in score (95% CI; p-value) 
3 Statistical significance as defined by what was reported in the manuscript for the primary outcome  
4 Number of trials (%) where the replicated initial sample size is within 10% of the reported target sample size 
5 Data presented as average difference in power (95% CI; p-value). If more than one primary outcome was specified in the manuscript, the primary outcome 
refers to the primary outcome used in the sample size calculation. Secondary outcomes refer to the average of the first two reported secondary outcomes. 
*1 Logistic regression could not be performed since all RCTs in the industry group (8 trials) had at least one discrepancy 
*2 Logistic regression could not be performed since no RCT in the industry group (13 trials) reported at least five of six items 
*3 Logistic regression could not be performed since all RCTs in the industry group (16 trials) reported all sample size assumptions 
*4 Linear regression could not be performed since all RCTs in the industry group (2 trials) could not have the primary post-hoc power calculated 
*5 Logistic regression could not be performed since all RCTs had a primary post-hoc power below the threshold 
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 Grouping One 
(Industry-only funding vs non-industry-
only funding) 
Grouping Two 
(any industry funding vs no industry 
funding) 
Trial Registration   
Adequately registered (n=143) 1.26 (0.32 to 4.91; 0.74) 1.15 (0.43 to 3.07; 0.78) 
Primary outcome discrepancy (n=56) 1.26 (0.16 to 9.65; 0.82) 1.29 (0.29 to 5.75; 0.74) 
Secondary outcome discrepancy (n=56) 0.32 (0.03 to 3.68; 0.40) 0.81 (0.08 to 8.04; 0.86) 
Any outcome discrepancy (n=56) *1 *1 
CONSORT - Abstract Adherence   
Title (n=168) 0.52 (0.16 to 1.68; 0.29) 1.16 (0.46 to 2.93; 0.75) 
Trial design (n=168) 2.45 (0.78 to 7.67 0.12) 2.29 (1.02 to 5.10; 0.04) 
Methods (5/6 items)1 (n=168) *2 0.36 (0.05 to 2.90; 0.28) 
Results/Conclusions (5/6 items)1 (n=168) 0.50 (0.06 to 4.07; 0.48) 0.96 (0.30 to 3.07; 0.95) 
Trial Registration (n=168) 0.74 (0.22 to 2.52; 0.63) 0.57 (0.23 to 1.36; 0.19) 
Overall score2 (n=168) -0.58 (-2.16 to 1.00; 0.47) 0.20 (-0.90 to 1.30; 0.72) 
Sample Size   
All sample size assumptions reported (n=83) *3 *3 
Statistically significant primary outcome3 (n=83) 1.92 (0.35 to 10.52; 0.44) 0.92 (0.31 to 2.77; 0.89) 
Replication of initial sample size calculation4 (n=70) 2.58 (0.47 to 14.31; 0.26) 2.55 (0.78 to 8.34; 0.11) 
Primary outcome post-hoc power5 (n=55) 0.40 (-0.04 to 0.85; 0.07) 0.04 (-0.27 to 0.35; 0.81) 
 For trials that are statistically significant3,5 (n=28) 0.07 (-0.22 to 0.35; 0.64) 0.00 (-0.26 to 0.26; 0.99) 
 For trials that are not statistically significant3,5 (n=27) *4 -0.02 (-0.18 to 0.14; 0.77) 
Secondary outcomes post-hoc power5 (n=71) 0.02 (-0.24 to 0.29; 0.86) -0.14 (-0.33 to 0.06; 0.16) 
 For trials that are statistically significant3,5 (n=38) -0.04 (-0.40 to 0.32; 0.83) -0.20 (-0.49 to 0.09; 0.18) 
 For trials that are not statistically significant3,5 (n=33) 0.04 (-0.30 to 0.37; 0.83) -0.05 (-0.26 to 0.15; 0.60) 
 Primary outcome ≥ 80% post-hoc power (n=55) 4.93 (0.42 to 58.57; 0.19) 0.88 (0.15 to 5.06; 0.89) 
 For trials that are statistically significant3 (n=28) 1.33 (0.11 to 16.74; 0.82) 0.60 (0.07 to 5.03; 0.64) 
 For trials that are not statistically significant3 (n=27) *5 *5 
Primary outcome ≥ 70% post-hoc power (n=55) 4.50 (0.38 to 53.29; 0.22) 0.80 (0.14 to 4.59; 0.80) 
 For trials that are statistically significant3 (n=28) 1.12 (0.09 to 14.20; 0.93) 0.50 (0.06 to 4.23; 0.53) 
 For trials that are not statistically significant3 (n=27) *5 *5 
Secondary outcomes ≥ 80% post-hoc power (n=71) 0.01 (-0.30 to 0.33; 0.94) -0.09 (-0.32 to 0.14; 0.46) 
 For trials that are statistically significant3 (n=38) -0.01 (-0.50 to 0.47; 0.95) -0.11 (-0.52 to 0.29; 0.57) 
 For trials that are not statistically significant3 (n=33) -0.03 (-0.30 to 0.23; 0.80) -0.04 (-0.20 to 0.13; 0.64) 
Secondary outcomes ≥70% post-hoc power (n=71) -0.05 (-0.40 to 0.30; 0.78) -0.15 (-0.41 to 0.11; 0.24) 
 For trials that are statistically significant3 (n=38) -0.13 (-0.66 to 0.40; 0.62) -0.24 (-0.68 to 0.20; 0.28) 
 For trials that are not statistically significant3 (n=33) -0.03 (-0.30 to 0.23; 0.80) -0.04 (-0.20 to 0.13; 0.64) 
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6.4 Discussion 
While there have been absolute increases to medical research funding in the United 
States, the overall proportions from each funding source have remained relatively 
constant.16 More trials registered in ClinicalTrials.gov from 2006 to 2014 have been 
funded by industry, but the proportion of industry-funded trials has not increased.17 In 
anesthesiology, the results are similar with the proportion of RCTs funded by industry 
showing a slight decrease from 2007 to 2016. In 2016, only 7% of RCTs were funded by 
solely industry sources and 18% by at least one industry source. By comparison, 37% of 
interventional RCTs registered in ClinicalTrials.gov,18 44% of pulmonary, critical care, 
and sleep medicine RCTs,19 60% of psychiatry RCTs,20 and 62% of rheumatoid arthritis 
RCTs21 were found to be funded by industry sources. This suggests that industry funding 
does not have as large an impact in anesthesiology, where most RCTs are funded by 
university, hospital, or government (Figure 6-1). 
There have been many studies comparing industry-sponsored studies to non-industry-
sponsored studies, with industry-sponsored studies historically being more likely to 
report favourable efficacy results, less likely to report evidence of harm, and more likely 
to report favourable conclusions.7,22,23 However, no difference was found when assessing 
whether the risk of bias (methodological quality scores, sequence generation, 
concealment of allocation, loss to follow-up, etc.) for trials differed by funding source, 
other than industry-sponsored trials being more likely to report adequate blinding.23 The 
current study explored facets of methodological quality that had not been commonly 
researched in terms of the funding source impact. Our analysis found no significant 
differences between industry funded RCTs and non-industry funded RCTs in terms of 
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trial registration, outcome switching, adherence to CONSORT for Abstracts, sample size 
calculations, or post-hoc power. With the wide 95% confidence intervals around our 
point estimates, either there was no industry funding effect or there were not enough 
RCTs present in the analysis to be able to detect a real effect (i.e., we lacked statistical 
power).  
For the outcomes concerning trial registration, no differences were found for whether a 
RCT was adequately registered, whether a RCT had at least one primary outcome 
discrepancy, or whether a RCT had at least one secondary outcome discrepancy. Though 
not significant, there was a trend that RCTs funded by industry were more likely to be 
adequately registered and have at least one primary outcome discrepancy, but less likely 
to have at least one secondary outcome discrepancy. This corresponds to a study using 
ClinicalTrials.gov records finding that compared to academic, non-profit, and 
government organizations, industry funded trials were more likely to be registered before 
or within three months of the trial start date.24 However, when the primary and secondary 
outcome discrepancy outcomes were combined into one composite outcome assessing 
whether a RCT had at least one discrepancy regardless of it being primary or secondary, 
logistic regression could not be performed since all RCTs funded by industry had at least 
one discrepancy.  
Even when using two grouping methods, one classifying RCTs into industry-only 
funding and one classifying RCTs into any industry funding, no differences were found 
when comparing to RCTs not funded by industry. From Table 6-2, the trial design 
criterion when comparing RCTs with any industry funding and no industry funding was 
the only regression model that was statistically significant. However, with wide 
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confidence intervals approaching an odds ratio of one and the high number of statistical 
tests performed, this marginally statistically significant result was possibly due to chance. 
Due to the low number of included RCTs, all journals were pooled together in the 
analyses. However, different journals had different proportions of RCTs being funded by 
industry sources, potentially influencing the results. 
These findings highlighted one of the major limitations of this study — adequate sample 
size. Since the number of RCTs was dependent on the number found in the journals from 
previous chapters, no a priori sample size calculations were performed. As a result, this 
study may have been underpowered to identify the effect industry funding may have had 
on RCT methodological quality, if such an effect truly existed. Having only a minority of 
RCTs funded by industry sources would exaggerate the problem of low sample size and 
contribute to the limitation of inadequate power. Another limitation was that data 
extraction for each RCT was performed by a single reviewer. To reduce potential error, 
all reviewers were trained prior to data extraction using the same guidelines and unclear 
variables were discussed during the process. RCTs where the funding source was not 
reported present another limitation, as it would not be apparent whether they were funded 
by industry or not. The proportion of RCTs with the funding source not reported 
decreased with each successive year measured. In 2016, only two journals had RCTs 
where the funding source was not reported, comprising 5% of eligible RCTs.  
In conclusion, a minority of RCTs published in the top six general anesthesiology 
journals were funded by industry sources. Contrary to our hypothesis, no methodological 
quality differences were found between industry and non-industry funded sources in 
terms of trial registration, outcome switching, adherence to CONSORT for Abstracts, 
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sample size calculations, or post-hoc power. The low number of industry-funded RCTs 
and lack of an industry funding effect suggest that, in contrast to other areas of medical 
research, the funding source may not be a significant problem in anesthesiology RCTs. 
However, more studies are needed to confirm the lack of an industry funding effect and 
more research needs to be conducted to determine whether other measures of quality of 
trial reporting are impacted by the funding source. 
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Chapter 7  
7 Integrated Discussion and General Conclusions  
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7.1 Overview 
This thesis is comprised of a series of four articles aimed at identifying potential areas 
where authors can reduce distortion by improving the quality of their research reporting. 
Randomized clinical trials (RCTs) from across the world were included, and a breakdown 
by country was created using Tableau Public 10.2 (Appendix E). Focusing on RCTs 
published in the top six general anesthesiology journals, the four overall objectives were: 
1) To determine the rate of adequate trial registration and whether the reported 
outcomes were the same as the outcomes originally registered in publicly 
available clinical trial registries 
2) To determine the degree of adherence to CONSORT for Abstracts reporting 
guidelines and the availability of that information in the full-text manuscript 
3) To determine the quality of sample size calculations and assess the post-hoc 
power for primary and secondary outcomes 
4) To determine the rate of industry funding and whether it has an effect on the 
methodological quality, as measured by the previous objectives  
7.2 Integrated Discussion of Results 
Methodological surveys are similar to systematic reviews since they both aggregate data 
from published studies. However, methodological surveys use information about how 
studies are conducted instead of the results of those studies. Chapters 3, 4, and 5 are 
methodological surveys while Chapter 6 explores the impact of funding on those 
measures of methodological quality. In each chapter, positives and negatives about the 
quality of anesthesiology RCTs were found. 
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Chapter 3 showed an increasing number of RCTs being adequately registered from 2007 
to 2015. However, only 38% of RCTs in 2015 were adequately registered. Of the 
adequately registered RCTs, 92% had at least one primary or secondary discrepancy 
between the registry entry and the published article, with 42% having at least one primary 
outcome discrepancy and 90% having at least one secondary outcome discrepancy. These 
results were similar to a previous study in 20131 and suggest that more work needs to be 
done to improve trial registration, both in terms of increasing prospective trial registration 
and ensuring that registry entries are followed. 
Chapter 4 assessed the adherence to the CONSORT for Abstracts guidelines in RCTs 
from 2010 and 2016. Consistent with previous research,2 many RCTs did not meet the 
CONSORT for Abstracts guidelines. Though improvement was seen from 2010 to 2016, 
the overall level of adherence was still lacking with around 75% of RCTs meeting fewer 
than half of the 16 criteria and no RCTs reporting all 16 items in the abstract. For most 
criteria, the information not reported in the abstract was available in the full-text, 
suggesting that abstracts were not adequately summarizing the entirety of the reported 
RCT. 
Chapter 5 showed similar trends to the previous two chapters with the sample size 
calculation quality increasing over time but still remaining inadequate in 2016. With 
analyses restricted to two-arm, parallel group, superiority RCTs, almost all RCTs from 
2016 performed a sample size calculation and 84% reported all necessary assumptions to 
allow for replication of the sample size calculation. However, similar to previous studies 
in top general medical journals and anesthesiology journals,3,4 around 30% of sample size 
calculation replications were more than 10% different from the target sample size 
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reported. More concerningly, the expected outcome values and variability were different 
from what was observed, with most RCTs having discrepancies between the expected 
and reported assumptions larger than 10%. In terms of post-hoc power, statistically 
significant RCTs had a higher primary outcome post-hoc power than non-statistically 
significant RCTs, as expected from theory.5 However, only 66% of statistically 
significant RCTs had a post-hoc primary outcome power of 80% or more, and the 
average post-hoc power for secondary outcomes was, as expected, even lower than that 
of the primary outcome.  
Chapter 6 further explored the measures of methodological quality described in previous 
chapters by comparing RCTs funded by industry to those not funded by industry. A 
minority of included RCTs were funded by industry sources, across all years. Two 
groupings were used to classify RCTs as industry-funded: only industry and any industry. 
However, neither showed a difference when compared to no industry funded in terms of 
trial registration, outcome discrepancies, adherence to CONSORT for Abstracts 
guidelines, quality of sample size calculations, or post-hoc power.  
7.3 General Conclusions 
In evidence-based medicine, RCTs (and systematic reviews of their results) are typically 
considered to be at the top of the evidence hierarchy due to their lower risk of bias 
relative to non-randomized trials.6 However, their findings may still be distorted if careful 
attention is not paid to the design and reporting quality. Trial registration helps to reduce 
both publication and outcome reporting bias,7 reducing the chance that the published 
literature is distorted in favour of statistically significant RCTs. Abstracts are intended to 
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be concise and accurate summaries of the entire study, and they are frequently assessed 
by readers who never read the full trial report. Therefore, abstract reporting guidelines 
should be followed more closely to ensure that all relevant information is included.8,9 
Since most of the information being left out of the abstract is later presented in the full-
text, adherence to the abstract reporting guidelines can be easily improved. Sample size 
calculations are intended as a guide to determine the ideal number of participants to be 
recruited, balancing the need to be able to detect a precise effect with the need to avoid 
exposing extra participants to potential risks.10 However, inaccuracies in sample size 
calculations may result in readers having a distorted understanding of the effects of an 
intervention, if not properly reported. Any discussion of potential literature distortion 
should also consider the possible impacts of funding source since there may be financial 
pressures to achieve certain results.11 
While the quality of reporting in anesthesiology RCTs has improved over time, this thesis 
identified several areas that can still be improved. In terms of design quality, trial 
registration and quality of sample size calculations need to be improved, while in terms 
of reporting quality, there needs to be improved adherence to abstract reporting 
guidelines and reduced discrepancies between registered and reported outcomes. Industry 
funding does not appear to be a major concern for anesthesiology RCTs with only a 
minority being industry-funded and no differences observed for the above measures of 
quality. When interpreting the findings from this thesis, careful consideration for the 
generalizability is needed as only RCTs from the top six general anesthesiology journals 
were included for analyses. As well, only a limited number of years were evaluated, 
reducing the ability to detect trend and differences over time due to the potential for 
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conflicting findings in unmeasured years. More research is needed to confirm the results 
of these studies as well as to identify potential tools that can be used to improve the 
quality of RCTs. More research is also needed to ensure that current trial registration 
policies, CONSORT for Abstracts reporting guidelines, and sample size calculation 
methods are suitable for reducing distortion in anesthesiology RCTs. 
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Appendices 
Appendix A: CONSORT for Abstracts checklist 
Items to include when reporting a randomized trial in a journal or conference abstract 
Item Description 
Title  Identification of the study as randomized 
Authors* Contact details for the corresponding author 
Trial design Description of the trial design (e.g. parallel, cluster, non-
inferiority) 
Methods  
  Participants Eligibility criteria for participants and the settings where the 
data were collected 
  Interventions Interventions intended for each group 
  Objective Specific objective or hypothesis 
  Outcome Clearly defined primary outcome for this report 
  Randomization How participants were allocated to interventions 
  Blinding (masking) Whether or not participants, care givers, and those assessing 
the outcomes were blinded to group assignment 
Results  
  Numbers randomized Number of participants randomized to each group 
  Recruitment Trial status 
  Numbers analysed Number of participants analysed in each group 
  Outcome For the primary outcome, a result for each group and the 
estimated effect size and its precision 
  Harms Important adverse events or side effects 
Conclusions General interpretation of the results 
Trial registration Registration number and name of trial register 
Funding Source of funding 
*this item is specific to conference abstracts 
Hopewell S, Clarke M, Moher D, et al. CONSORT for reporting randomised trials in 
journal and conference abstracts. Lancet. 2008;371(9609):281-283. doi:10.1016/S0140-
6736(07)61835-2. 
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Appendix B: Sample email to corresponding authors 
 
Dear Dr Corresponding Author, 
 
We are researchers from the University of Western Ontario in London, Ontario, Canada. 
We are conducting a study of published literature in Anesthesiology journals. We are 
contacting you because you were the corresponding author on the paper "Name of 
published article" published in "Journal" in Month, Year. 
 
One of the items we are studying is clinical trial registration (such as at a site like 
www.clinicaltrials.gov). We could not find any evidence that your trial was registered, 
and hence we are writing to see if your trial was indeed registered at any clinical trial 
registry. 
 
If your trial was registered, would you please reply to this email to tell us where it was 
registered? 
 
Even if your paper was not registered, we would appreciate it if you could reply to this 
email to let us know that it wasn't. 
 
Your assistance is greatly appreciated. 
 
Kind regards, 
 
Researcher 
 
on behalf of the Research Team. 
 
--------------- 
Study Contact: Philip M Jones, MD MSc (Clinical Trials) FRCPC (Principal 
Investigator) 
Associate Professor 
Department of Anesthesia & Perioperative Medicine 
Program in Critical Care, Department of Medicine 
Department of Epidemiology & Biostatistics 
University of Western Ontario / London Health Sciences Centre 
 
(Office use only - Article ID: Article ID) 
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Appendix C: Differences between outcomes when comparing the published trial to the trial registry among adequately 
registered trials (stratified by journal) 
A: Data presented are the number of trials (%). All percentages are column percentages with the denominator set to the total number of trials published. 
B: Data presented are the proportion of trials where the identified discrepancy favoured statistical significance (see article text for details). 
All uses of ‘registered’ pertain to the outcome as registered in the trial registry and all uses of ‘reported’ pertain to the outcome as reported in the published 
manuscript. If there are one or more occurrences of the discrepancy in a trial, the trial will be counted as having the described discrepancy. Subcategories are not 
mutually exclusive so if individual studies have more than one discrepancy, the sum of the subcategories will be larger than the parent category.  
“N/A” represents values where it could not be determined whether the discrepancy favoured statistical significance: either when the discrepancy involved an 
outcome not being reported or when there were no studies with the discrepancy. 
 
a Trials with at least one discrepancy between the primary or secondary outcomes reported in the published article and those registered in the trial registry. 
b Trials with at least one discrepancy between the primary outcome reported in the published article and that registered in the trial registry. 
c Trials with at least one discrepancy among any of the secondary outcomes reported in the published article and those registered in the trial registry. 
* While the wording is slightly different, both rows are equivalent, as both show a registered primary outcome being reported as a secondary outcome.  
** While the wording is slightly different, both rows are equivalent, as both show a registered secondary outcome being reported as a primary outcome. 
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Anaesthesia 
(n=8) 
Anesthesia & 
Analgesia 
(n=18) 
Anesthesiology 
(n=16) 
British Journal 
of Anaesthesia 
(n=31) 
Canadian 
Journal of 
Anesthesia 
(n=16) 
European 
Journal of 
Anaesthesiology 
(n=13) 
 A B A B A B A B A B A B 
Trials with any primary or secondary outcome 
discrepancya 
4 (50%) 1.00 17 (94%) 0.53 14 (88%) 0.71 30 (97%) 0.67 16 (100%) 0.75 13 (100%) 0.15 
             
Trials with primary outcome discrepanciesb 1 (13%) 1.00 9 (50%) 0.44 7 (44%) 0.86 20 (65%) 0.65 5 (31%) 1.00 4 (31%) 0.25 
Registered primary outcome not reported 
as primary outcome  
0 (0%) N/A 6 (33%) 0.17 3 (19%) 0.00 12 (39%) 0.17 2 (13%) 0.50 2 (15%) 0.00 
Registered primary outcome not 
reported 
0 (0%) N/A 3 (17%) N/A 2 (13%) N/A 4 (13%) N/A 1 (6%) N/A 1 (8%) N/A 
Registered primary outcome reported 
as secondary outcome* 
0 (0%) N/A 3 (17%) 0.33 1 (6%) 0.00 10 (32%) 0.20 1 (6%) 1.00 1 (8%) 0.00 
Reported primary outcome not registered 
as primary outcome 
0 (0%) N/A 5 (28%) 0.60 4 (25%) 1.00 12 (39%) 0.83 4 (25%) 1.00 4 (31%) 0.25 
Reported primary outcome not 
registered 
0 (0%) N/A 4 (22%) 0.50 3 (19%) 1.00 11 (35%) 0.82 2 (13%) 1.00 3 (23%) 0.00 
Reported primary outcome registered 
as secondary outcome** 
0 (0%) N/A 1 (6%) 1.00 1 (6%) 1.00 1 (3%) 1.00 2 (13%) 1.00 1 (8%) 1.00 
Timing of reported primary outcome 
different from primary outcome registered 
1 (13%) 1.00 4 (22%) 0.00 3 (19%) 1.00 4 (13%) 0.50 0 (0%) N/A 1 (8%) 0.00 
             
Trials with secondary outcome 
discrepanciesc 
4 (50%) 0.75 16 (89%) 0.44 13 (81%) 0.62 30 (97%) 0.53 16 (100%) 0.69 12 (92%) 0.17 
Registered secondary outcome not 
reported as secondary outcome 
0 (0%) N/A 5 (28%) 0.20 5 (31%) 0.20 7 (23%) 0.14 7 (44%) 0.29 4 (31%) 0.25 
Registered secondary outcome not 
reported 
0 (0%) N/A 4 (22%) N/A 4 (25%) N/A 6 (19%) N/A 5 (31%) N/A 3 (23%) N/A 
Registered secondary outcome 
reported as primary outcome** 
0 (0%) N/A 1 (6%) 1.00 1 (6%) 1.00 1 (3%) 1.00 2 (13%) 1 1 (8%) 1 
Reported secondary outcome not 
registered as secondary outcome  
3 (38%) 1.00 16 (89%) 0.38 12 (75%) 0.50 30 (97%) 0.50 14 (88%) 0.71 10 (77%) 0.00 
Reported secondary outcome not 
registered 
3 (38%) 1.00 16 (89%) 0.38 12 (75%) 0.50 29 (94%) 0.45 14 (88%) 0.64 10 (77%) 0.00 
Reported secondary outcome 
registered as primary outcome* 
0 (0%) N/A 3 (17%) 0.33 1 (6%) 0.00 10 (32%) 0.20 1 (6%) 1.00 1 (8%) 0.00 
Timing of reported secondary outcome 
different from secondary outcome 
registered 
1 (13%) 0.00 5 (28%) 0.40 1 (6%) 1.00 6 (19%) 0.17 3 (19%) 0.33 4 (31%) 0.25 
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Appendix D: Adapted version of CONSORT for Abstracts statement explanations 
 
1. Abstract (if criteria reported in abstract) 
2. FulltextOnly (if criteria not reported in abstract but reported in fulltext) 
3. NotReported (if criteria not reported in abstract and not reported in fulltext) 
 
Criteria Explanation 
Title: 
Identification of 
the study as 
randomized 
Authors should state explicitly in the title that the participants were 
randomly assigned to their comparison groups.  
- Title - Criteria reported in title (counts if randomized is in the 
subtitle) 
- Abstract - Criteria not reported in title but reported in abstract  
- FulltextOnly - Criteria not reported in title or abstract but 
reported in fulltext 
- NotReported - Criteria not reported in title, abstract, or 
fulltext" 
Trial Design:  
Description of 
the trial design 
The design of the trial should be described: 
E.G. parallel group, cluster randomized, crossover, factorial, 
superiority, equivalence/noninferiority, etc. 
Note: Trial design needs to be clear. I.E. If it is a superiority trial, 
should state that design is to test whether one is better. Parallel group 
does not need to be explicitly stated if it is mentioned that subjects are 
randomized to different groups.  
- If authors only state that they are comparing two interventions 
(not to see whether one is better or to see whether they are 
equivalent), no credit should be given since they are not clear 
enough. However, if the sample size calculation shows that 
superiority is hypothesized, “trial design” would be credited 
with “full text only.” 
Participants:  
Eligibility 
criteria for 
participants 
and the settings 
A clear description of BOTH the trial participants and setting in 
which they were studied is needed. Participant eligibility criteria 
may relate to demographics, clinical diagnosis, and comorbid 
conditions while the trial may be performed in a particular setting 
(e.g. primary, secondary, or tertiary care).  
Interventions: 
Interventions 
intended for 
each group 
The essential features of the experimental and comparison 
interventions should be described. Authors should report details about 
the interventions (e.g. dose, route of administration, duration of 
administration, frequency, surgical procedure, or manufacturer of 
inserted device). 
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- As long as clear and specific what was used 
Objective: 
Specific 
objective or 
hypothesis 
A clear statement of the specific objective or hypothesis addressed in 
the trial. If more than one objective is addressed, the main objective 
(i.e. based on the prespecified primary outcome) should be indicated 
and only key secondary objectives stated. 
- If authors only state that they are comparing two interventions 
(not to see whether one is better or to see whether they are 
equivalent), no credit should be given since they are not clear 
enough. 
Outcome: 
Clearly defined 
primary 
outcome for 
this report 
Authors should explicitly state the primary outcome for the trial and 
when it was assessed (e.g., the time frame over which it was 
measured). 
- Need to specify “primary outcome/endpoint” 
Randomization: 
How 
participants 
were allocated 
to interventions 
The method for assigning participants to interventions is clearly 
described.  
Note: Need to specify how participants were allocated (just a 
computer-generated randomization list is not enough) 
 
Examples of approaches used to ensure adequate concealment 
include: centralised (e.g. allocation by a central office) or pharmacy-
controlled randomization; sequentially numbered identical containers 
that are administered serially to participants; on-site computer system 
combined with allocations kept in a locked, unreadable computer file 
that investigators can access only after the characteristics of an 
enrolled participant are entered; and sequentially numbered, opaque 
sealed envelopes. 
Blinding 
(masking): 
Participants, 
caregivers, or 
outcome 
assessors 
blinded to 
group 
assignment 
It is important that authors describe whether or not participants, those 
administering the intervention (usually health-care providers), and 
those assessing the outcome (the data collectors and analysts) were 
blinded to the group allocation. Authors should report if any form of 
blinding (such as blinding of data analysts) was used. 
- If there is no blinding, authors should state “no blinding, no 
masking, etc.” in order to count 
- Using a placebo counts as participant blinding 
- Using terms such as “single” or “double” blinding fulfills this 
criteria 
Blinding refers to the practice of keeping the trial participants, care 
providers, data collectors, and sometimes those analysing the data, 
unaware of which intervention is being administered to which 
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participant, so that they will not be influenced by that knowledge. The 
term masking is sometimes used instead of blinding. 
Numbers 
randomized: 
Subjects 
randomized to 
each group 
The number of participants randomized to each intervention group is 
an essential element of the results of a trial. 
- Only counts if a number is provided for each group 
Recruitment:  
Trial status 
Authors should describe the status of the trial and whether it is still 
ongoing, closed to recruitment, or closed to follow-up. If the trial has 
stopped earlier than planned it is important to say why.  
- Note: If they reach their target sample size, we can assume 
that the trial is completed (full-text only if target sample size 
and number studied is only in full-text) 
- Okay if they provided a date of when data collection ended 
Possible reasons for early termination include: slow accrual rates, 
poor data quality, poor adherence, resource deficiencies, unacceptable 
harms or large benefits, or emerging information that makes the trial 
irrelevant, unnecessary, or unethical. 
Numbers 
analysed:  
Participants 
analysed in 
each group 
Authors should report the number of participants included in the 
analysis for each intervention group. 
- State numbers analyzed for entire trial or for primary outcome 
(stating for a secondary outcome only does not count I.E. 
10/20 people achieved the secondary outcome is not enough 
but 10/20 people achieved the primary outcome is enough) 
- Only counts if a number is provided for each group 
Outcome: A 
result for each 
group, overall 
effect size, and 
precision 
For the primary outcome, authors should report trial results as a 
summary of the outcome in each group (e.g. the number of 
participants with or without the event, or the mean and standard 
deviation of measurements), together with the contrast between 
groups known as the effect size (with uncertainty such as 95% CI).  
For binary outcomes, the effect size could be the relative risk, relative 
risk reduction, odds ratio, or risk difference. For survival time data, 
the measurement could be the hazard ratio or difference in median 
survival time. For continuous data, the effect measure is usually the 
difference in means.  
- For primary outcome only (need all of the following elements) 
- Continuous: Mean of each group, effect size (difference 
between groups), 95% CI (some measure of uncertainty for 
these values) 
- Binary (# with/without event in each group, effect size, 95% 
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CI 
- Effect size (comparison between groups) can be difference, 
ratio, odds, etc. 
Authors should present confidence intervals for the contrast between 
groups and as a measure of the precision (uncertainty) of the estimate 
of the effect. 
For abstracts not reporting the ‘‘primary’’ outcome of the trial (e.g. 
abstracts focusing on safety data or economic impacts), the secondary 
nature of the outcomes should be indicated, and, 
where possible, sufficient details of the primary outcome should be 
included to allow other findings to be taken in the proper context. 
Harms: 
Important 
adverse events 
or side effects 
Authors should describe any important adverse (or unexpected) 
effects of an intervention in the abstract. If no important adverse 
events have occurred, the authors should state this explicitly. 
Conclusions: 
General 
interpretation 
of the results 
The conclusions of the trial, consistent with the results reported in the 
abstract, should be clearly stated along with their clinical application 
(avoiding over-generalisation). Authors should balance the benefits 
and harms in their conclusions. Where applicable, authors should also 
note whether additional studies are required before the results are 
used in clinical settings. 
Trial 
registration: 
Registration 
number and 
name of trial 
register 
In an abstract reporting a trial, authors should provide details of the 
trial registration number and name of trial register.  
- Automatically completed as “notreported” if trial marked as 
not registered on registration tab OR registration info provided 
after email to author. 
Funding: 
Source of 
funding 
Authors should report the source of funding for the trial as this is 
important information for readers assessing a trial. Similarly, authors 
should report any other sources of support, such as in the preparation 
of the abstract, presentation, or manuscript. 
- Funding source needs to be in abstract in order to input 
“abstract” 
1. Hopewell S, Clarke M, Moher D, et al. (2008) CONSORT for Reporting Randomized 
Controlled Trials in Journal and Conference Abstracts: Explanation and Elaboration. 
PLoS Med 5:e20. doi: 10.1371/journal.pmed.0050020 
2. Hopewell S, Clarke M, Moher D, et al. (2008) CONSORT for reporting randomised 
trials in journal and conference abstracts. Lancet 371:281–3. doi: 10.1016/S0140-
6736(07)61835-2 
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Appendix E: Adherence to CONSORT-Abstract reporting items in RCTs (breakdown by journal in 2016) 
Abstract: Proportion of trials with the checklist item reported  
Full-text only: Of trials with the checklist item not reported in the abstract, the proportion of trials with the checklist item reported in the 
manuscript  
A=Anaesthesia (n=38); B=Anesthesia & Analgesia (n=33); C=Anesthesiology (n=26); D=British Journal of Anaesthesia (n=34); E=Canadian 
Journal of Anesthesia (n=21); F= European Journal of Anaesthesiology (n=24) 
p-value: Pearson's chi-squared test for differences between journals 
 
 Abstract Full-text only 
 A B C D E F p A B C D E F p 
Title 0.35 0.49 0.41 0.53 0.76 0.44 0.005 1 1 1 1 1 1 N/A 
Trial Design 0.09 0.20 0.57 0.29 0.24 0.29 <0.001 0.56 0.50 0.39 0.67 0.32 0.60 <0.001 
Methods               
Participants 0.20 0.04 0.33 0.41 0.05 0.25 <0.001 0.79 0.50 0.39 0.26 0.73 0.25 <0.001 
Interventions 0.42 0.71 0.78 0.71 0.62 0.78 0.001 0.57 0.29 0.22 0.29 0.38 0.22 0.001 
Objective 0.07 0.39 0.43 0.30 0.32 0.32 0.001 0.54 0.26 0.47 0.41 0.46 0.29 0.015 
Outcome 0.19 0.38 0.49 0.41 0.46 0.29 <0.001 0.58 0.22 0.39 0.21 0.38 0.12 <0.001 
Randomization 0.01 0.02 0.02 0.01 0 0.01 0.434 0.81 0.73 0.80 0.77 0.89 0.65 0.011 
Blinding (masking) 0.19 0.44 0.49 0.44 0.30 0.40 0.001 0.70 0.46 0.39 0.44 0.65 0.41 <0.001 
Results               
Numbers 
randomized 
0.53 0.31 0.29 0.39 0.49 0.37 0.946 0.47 0.47 0.63 0.57 0.46 0.51 0.946 
Recruitment 0.05 0.07 0.06 0.09 0.19 0.18 0.005 0.90 0.78 0.90 0.90 0.78 0.63 0.027 
Numbers analyzed 0.15 0.14 0.27 0.17 0.24 0.12 0.053 0.85 0.76 0.71 0.83 0.73 0.75 0.053 
Outcome 0.10 0.27 0.33 0.16 0.51 0.09 <0.001 0.17 0.16 0.27 0.09 0.14 0.04 0.088 
Harms 0.37 0.57 0.51 0.64 0.54 0.60 0.038 0.41 0.30 0.31 0.24 0.16 0.34 0.003 
Conclusions 0.72 0.98 1 0.97 0.95 0.97 <0.001 0.23 0.02 0 0.01 0.05 0.01 <0.001 
Trial registration 0.01 0.01 0 0.53 0.54 0.35 <0.001 0.25 0.51 0.65 0.14 0.16 0.06 <0.001 
Funding 0 0 0 0 0 0 N/A 0.84 0.82 1 0.76 0.81 0.69 <0.001 
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Appendix F: Distribution of country origin for included RCTs 
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